plxp20220331

0001437749-22-012225.txt : 20220513 0001437749-22-012225.hdr.sgml : 20220513 20220513073032 ACCESSION NUMBER: 0001437749-22-012225 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PLx Pharma Inc. CENTRAL INDEX KEY: 0001497504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271707962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36351 FILM NUMBER: 22920241 BUSINESS ADDRESS: STREET 1: 9 FISHERS LANE STREET 2: SUITE E CITY: SPARTA STATE: NJ ZIP: 07871 BUSINESS PHONE: (713) 842-1249 MAIL ADDRESS: STREET 1: 9 FISHERS LANE STREET 2: SUITE E CITY: SPARTA STATE: NJ ZIP: 07871 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20140313 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, LLC DATE OF NAME CHANGE: 20100726 10-Q 1 plxp20220331_10q.htm FORM 10-Q plxp20220331_10q.htm

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

☒	Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended March 31, 2022

☐	Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-36351

Commission File Number 001-36351

PLx Pharma Inc.

(Exact name of registrant as specified in its charter)

Delaware

46-4995704

State or other jurisdiction of

incorporation or organization

(I.R.S. Employer

Identification No.)

9 Fishers Lane, Suite E

Sparta, NJ

07871

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (973) 409-6541

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.001 par value	PLXP	The NASDAQ Capital Market

(Title of each class)	(Trading Symbol)	(Name of each exchange on which registered)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

☒Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Table of Contents

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of May 10, 2022, there were 27,539,229 shares of common stock, $0.001 par value, issued and outstanding.

Table of Contents

PLx Pharma Inc.

Table of Contents

		Page #

PART I -	FINANCIAL INFORMATION	6

Item 1.	Consolidated Financial Statements (unaudited)	6

	Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 (unaudited)	6

	Consolidated Statements of Operations for the Three Months Ended March 31, 2022 and 2021 (unaudited)	7

	Consolidated Statements of Changes in Series A and Series B Convertible Preferred Stock and Stockholders’ Equity for the Three Months Ended March 31, 2022 and 2021 (unaudited)	8

	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021 (unaudited)	9

	Notes to Consolidated Financial Statements (unaudited)	10

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	21

Item 4.	Controls and Procedures	21

PART II -	OTHER INFORMATION	22

Item 1.	Legal Proceedings	22

Item1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosure	22

Item 5.	Other Information	22

Item 6.	Exhibits	22

	Signatures	24

	Certificates

Table of Contents

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In this quarterly report, we refer to PLx Pharma Inc., together with its subsidiary, as the “Company,” “we,” “our” or “us.” All statements other than statements of historical facts contained herein, including statements regarding our future results of operations and financial position, strategy and plans, and our expectations for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect” or the negative version of these words and similar expressions are intended to identify forward-looking statements.

We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A “Risk Factors.” In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances included herein may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

	●	our ability to maintain regulatory approval of VAZALORE™ 81 mg and VAZALORE™ 325 mg (referred to together as “VAZALORE”) and any future product candidates;
	●	the benefits of the use of VAZALORE;
	●	the projected dollar amounts of future sales of established and novel technologies designed to deliver oral non-steroidal anti-inflammatory drugs (“NSAIDs”) and other analgesics while limiting direct contact with the stomach lining;
	●	our ability to successfully further commercialize our VAZALORE products, or any future product candidates;
	●	the rate and degree of market acceptance of our VAZALORE products or any future product candidates;
	●	our expectations regarding government and third-party payor coverage and reimbursement;
	●	our ability to scale up manufacturing of our VAZALORE products to commercial scale;
	●	our ability to successfully build and maintain a specialty sales force and commercial infrastructure or collaborate with a firm that has these capabilities;
	●	our ability to compete with companies currently producing gastrointestinal(“GI”)-safety designed technologies for oral NSAIDs and other analgesics;
	●	our reliance on third parties to conduct our clinical studies;
	●	our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us;
	●	our reliance on third-party warehouse and distribution centers to store and deliver our products to retail trade locations;
	●	our reliance on retail trade customers to maintain an adequate supply of VAZALORE on store shelves or displays;
	●	our ability to obtain supply of raw materials;
	●	our reliance on our current and any potential collaboration partners’ performance over which we do not have control;
	●	our ability to retain and recruit key personnel, including development of a sales and marketing function;
	●	our ability to obtain and maintain intellectual property protection for our VAZALORE products or any future product candidates;
	●	our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for or ability to obtain additional financing;
	●	our ability to identify, develop, acquire and in-license new products and product candidates;
	●	our ability to successfully establish and successfully maintain appropriate collaborations and derive significant revenue from those collaborations, including but not limited to any milestone payments or royalties;
	●	legal, political, judicial and regulatory changes;
	●	any impact of the COVID-19 pandemic on our business and financial results;
	●	our financial performance;
	●	developments and projections relating to our competitors or our industry; and
	●	our ability to access additional capital due to fluctuations in the U.S. stock market.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. In addition, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Any forward-looking statement made by us in this quarterly report speaks only as of the date on which it is made. We disclaim any duty to update any of these forward-looking statements after the date of this quarterly report to conform these statements to actual results or revised expectations.

Table of Contents

Other risks may be described from time to time in our filings made under applicable securities laws. New risks emerge from time to time. It is not possible for our management to predict all risks. All forward-looking statements in this quarterly report speak only as of the date made and are based on our current beliefs and expectations. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

NOTE REGARDING TRADEMARKS

We own various U.S. federal trademark registrations and applications and unregistered trademarks, trade names and service marks, including:

	●	PLX®

	●	PLX PHARMA®

	●	PLXGUARD™

	●	VAZALORE®

	●	FIRST LIQUID-FILLED ASPIRIN CAPSULES®

	●

Solely for convenience, the trademarks and trade names in this quarterly report are sometimes referred to without the ® or ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies, products or services.

Table of Contents

PART I.

FINANCIAL INFORMATION

ITEM 1.

CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

PLx Pharma Inc.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share data)

	March 31, 2022			December 31, 2021
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	52,499		$	69,392
Accounts receivable		698			634
Inventory, net		3,839			2,458
Prepaid expenses and other current assets		712			992
TOTAL CURRENT ASSETS		57,748			73,476
NON-CURRENT ASSETS
Property and equipment, net		828			858
Right of use assets		204			230
Goodwill		2,061			2,061
Security deposit		17			17
TOTAL ASSETS	$	60,858		$	76,642

LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable and accrued liabilities	$	12,716		$	10,600
Accrued bonuses		394			1,163
Other current liabilities		120			116
TOTAL CURRENT LIABILITIES		13,230			11,879
NON-CURRENT LIABILITIES
Warrant liability		5,410			12,818
Accrued dividends		129			129
Other liabilities		106			136
TOTAL LIABILITIES		18,875			24,962

Series A convertible preferred stock: $0.001 par value; liquidation value of $12,642,000; 45,000 shares authorized, 12,642 issued and outstanding at March 31, 2022 and December 31, 2021		13,708			13,708
Series B convertible preferred stock: $0.001 par value; liquidation value of $2,492,722; 25,000 shares authorized, 2,364 issued and outstanding at March 31, 2022 and December 31, 2021		2,306			2,306

Commitments and contingencies

STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 930,000 shares authorized; none issued and outstanding at March 31, 2022 and December 2021		-			-
Common stock; $0.001 par value; 100,000,000 shares authorized; 27,539,229 shares issued and outstanding at March 31, 2022 and December 31, 2021		28			28
Additional paid-in capital		185,000			183,912
Accumulated deficit		(159,059	)		(148,274	)
TOTAL STOCKHOLDERS' EQUITY		25,969			35,666
TOTAL LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	$	60,858		$	76,642

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

PLx Pharma Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except share and per share data)

	Three Months Ended March 31,
	2022			2021
REVENUES:
Net sales	$	2,083		$	-
TOTAL REVENUES		2,083			-

Costs of sales		1,169			-
GROSS PROFIT		914			-

OPERATING EXPENSES:
Research and development		654			959
Selling, marketing and administrative		18,456			2,636
TOTAL OPERATING EXPENSES		19,110			3,595
OPERATING LOSS		(18,196	)		(3,595	)

OTHER INCOME (EXPENSE):
Interest income (expense), net		3			(10	)
Change in fair value of warrant liability		7,408			(7,935	)
TOTAL OTHER INCOME (EXPENSE)		7,411			(7,945	)

LOSS BEFORE INCOME TAXES		(10,785	)		(11,540	)
Income taxes		-			-
NET LOSS		(10,785	)		(11,540	)

Preferred dividends		-			(322	)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(10,785	)	$	(11,862	)

Net loss per common share, basic and diluted	$	(0.39	)	$	(0.73	)

Weighted average shares of common shares, basic and diluted		27,539,229			16,361,583

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

PLx Pharma Inc.

CONSOLIDATED STATEMENTS OF CHANGES IN SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK

AND STOCKHOLDERS' EQUITY

(Unaudited)

(in thousands, except per share data)

For the Three Months Ended March 31, 2022 and 2021

	Temporary Equity								Permanent Equity
	Series A Convertible Preferred Stock				Series B Convertible Preferred Stock				Common stock			Additional paid-in			Accumulated			Total stockholders'
	Shares		Amount		Shares		Amount		Shares	Amount		capital			deficit			equity

Balance at December 31, 2021		12,642	$	13,708		2,364	$	2,306	27,539,229	$	28	$	183,912		$	(148,274	)	$	35,666

Stock-based compensation expense													1,088						1,088
Net loss																(10,785	)		(10,785	)
Balance at March 31, 2022		12,642	$	13,708		2,364	$	2,306	27,539,229	$	28	$	185,000		$	(159,059	)	$	25,969


Balance at December 31, 2020		15,000	$	13,662		8,000	$	7,723	13,911,633	$	14	$	91,203		$	(102,149	)	$	(10,932	)

Stock-based compensation expense													573						573
Series A Preferred - declared dividends													(217	)					(217	)
Series B Preferred - declared dividends													(105	)					(105	)
Financing									8,924,700		9		66,873						66,882
Net loss																(11,540	)		(11,540	)
Balance at March 31, 2021		15,000	$	13,662		8,000	$	7,723	22,836,333	$	23	$	158,327		$	(113,689	)	$	44,661

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

PLx Pharma Inc.

CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

(in thousands)

	Three months ended March 31,
	2022			2021

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(10,785	)	$	(11,540	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		30			27
Stock-based compensation		1,088			573
Amortization of right of use assets		26			77
Amortization of debt discounts and issuance costs		-			3
Change in fair value of warrant liability		(7,408	)		7,935
Loss on sale of property and equipment		-			28
Changes in operating assets and liabilities
Accounts receivable		(64	)		-
Inventory		(1,381	)		-
Prepaid expenses and other assets		280			138
Accounts payable and accrued liabilities		2,116			100
Accrued bonuses		(769	)		(938	)
Accrued interest		-			(597	)
Other current and long-term liabilities		(26	)		(88	)
Net cash used in operating activities		(16,893	)		(4,282	)

CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stock		-			66,882
Repayments of long-term debt		-			(625	)
Net cash provided by financing activities		-			66,257

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(16,893	)		61,975
Cash and cash equivalents, beginning of period		69,392			22,449
Cash and cash equivalents, end of period	$	52,499		$	84,424

SUPPLEMENTAL INFORMATION
Cash paid during the period for:
Income taxes	$	-		$	-
Interest	$	-		$	602

NON-CASH INVESTING AND FINANCING TRANSACTIONS
Preferred stock dividends	$	-		$	322

See accompanying notes to unaudited consolidated financial statements.

Table of Contents

PLx Pharma Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2022

(unaudited)

NOTE 1. BACKGROUND AND ORGANIZATION

Business Operations

PLx Pharma Inc. (the “Company”, “we”, “our” or “us”), together with its subsidiary PLx Opco Inc., is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (“APIs”) are absorbed in the gastrointestinal ("GI") tract via its clinically-validated and patent-protected PLxGuard™ technology. The Company has two Food and Drug Administration (“FDA”) approved products, VAZALORE® 81 mg and VAZALORE® 325 mg (referred to together as “VAZALORE”), which are liquid-filled aspirin capsules for over-the-counter distribution ("OTC").

Impact of COVID-19 Pandemic on Financial Statements

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed and continue to enforce quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses.

In response to COVID-19, the Company has not experienced a significant disruption or delay in the development, manufacturing or sale of VAZALORE, and has not otherwise experienced any significant negative impact on its financial condition, results of operations or cash flows. However, the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company has not experienced any significant negative impact on its March 31, 2022 unaudited consolidated financial statements related to COVID-19.

NOTE 2. LIQUIDITY

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations and potential other funding sources, in addition to cash on-hand, to meet its obligations as they become due.

The Company had not generated any revenue from the sale of products prior to the quarter ended September 30, 2021 and has incurred operating losses in each year since it commenced operations. The Company began generating revenue in the U.S. from its sales of VAZALORE in the third quarter of 2021. The Company expects to continue to incur significant operating expenses and operating losses for the foreseeable future as the Company continues the commercialization of VAZALORE. Additionally, as of March 31, 2022, the Company had entered into media and advertising commitments for VAZALORE of $2.9 million which are expected to be paid in the second quarter of 2022. Further, the Company has supply agreements with its contract manufacturer and packager for VAZALORE which contain minimum annual purchase commitments that started in 2021 and continue through 2025; the minimum annual purchase commitments are intended to ensure that manufactured product is available when required to enable the Company to meet its expected market demand for VAZALORE.

As of March 31, 2022, the Company had working capital of $44.5 million, including cash and cash equivalents of $52.5 million. Although the achievement of future profitable operations and the ability to generate sufficient cash from operations is uncertain at this time, the Company’s cash on hand at March 31, 2022 supports that the Company can fund its obligations for at least one year from the date these financial statements were issued and mitigates the substantial doubt consideration.

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting and Principles of Consolidation

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, PLx Opco Inc. All significant intercompany balances and transactions have been eliminated within the unaudited consolidated financial statements.

Table of Contents

Use of Estimates

The preparation of our unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, the fair value of warrant liability, the fair value of stock-based compensation, trade promotional allowances, allowance for inventory obsolescence, and deferred taxes and associated valuation allowance. Actual results could differ from those estimates.

Inventory

Inventory is stated at the lower of cost or net realizable value, using the first-in first-out method based on actual costs. Inventory as of March 31, 2022 and December 31, 2021 was comprised of the following:

Description	March 31, 2022		December 31, 2021
		(in thousands)
Raw Materials	$	164	$	132
Work-in-Progress		1		338
Finished Goods		3,674		1,988
Total Inventory	$	3,839	$	2,458

The Company regularly reviews inventory quantities on hand and assesses the need for an allowance for obsolescence based on estimates of net realizable value. The allowance for obsolete inventory as of March 31, 2022 and December 31, 2021 was not material.

Revenue Recognition

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit.

The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 mg and 325 mg doses in the third quarter of 2021 and recognizes revenue, at a point in time, when control of a promised good is transferred to a customer in an amount that reflects consideration that the Company expects to be entitled to in exchange for that good. This occurs either when the finished goods are received by the customer or when a product is picked up by the customer or the customer’s carrier. The Company recognized total revenue from sales of VAZALORE of $2.1 million with $1.7 million or 79% of net sales for the 81 mg dose and $0.4 million or 21% of net sales for the 325 mg dose for the three months ended March 31, 2022.

Nature of Goods and Services

The Company generates revenue from the sale of its VAZALORE products through a broad distribution platform that includes drugstores, mass merchandisers, grocery stores, and e-commerce channels, all of which sell its products to consumers. Finished goods products are typically shipped FOB destination and accordingly, the Company recognizes revenue upon delivery to the customer or pick-up by the customer’s carrier.

Satisfaction of Performance Obligations

The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. The Company had no unsatisfied performance obligations or deferred revenue as of March 31, 2022.

Table of Contents

Variable Consideration

Provisions for certain customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales, based on an estimate of future returns, and customer prompt payment discounts, redemption of coupons by consumers and trade promotional allowances paid to customers. These allowances cover extensive promotional activities, primarily comprised of cooperative advertising, slotting, coupons, periodic price reduction arrangements, and other in-store displays.

The reserves for sales returns and consumer and trade promotion obligations are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses trend experience and coupon redemption inputs to determine coupon reserve requirements and uses forecasted customer and sales organization inputs, and historical trend analysis for consumer brands to determine the reserves for other promotional activities and sales returns. The balance of reserves for sales returns and consumer and trade promotion obligations, reflected in the accompanying unaudited consolidated balance sheets in accounts payable and accrued liabilities, was $1.0 million as of March 31, 2022 and $1.3 million as of December 31, 2021.

Advertising

Advertising costs are expensed as they are incurred. The Company incurred advertising costs of $9.6 million during the three months ended March 31, 2022, which are included in SM&A expense in the unaudited consolidated statements of operations, and did not have any advertising costs during the three months ended March 31, 2021.

Income (Loss) Per Share

In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series A convertible preferred stock (the “Series A Preferred Stock”) and the Series B convertible preferred stock (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, collectively the “Preferred Stock”) contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the Preferred Stock and excludes the impact of those shares from the denominator.

In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the Preferred Stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock using the if-converted method.

Due to net losses, none of the participating securities nor potential dilutive securities had a dilutive impact during the three months ended March 31, 2022 and 2021.

The following table sets forth the potential dilutive securities:

	March 31, 2022		March 31, 2021
Stock Options		4,189,006		3,033,047
Warrants		6,596,096		7,935,503
Convertible Preferred Stock		6,476,275		9,517,191
Total Potential Dilutive Shares		17,261,377		20,485,741

Table of Contents

Recent Accounting Developments

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is designed to provide financial statement users with more information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. When determining such expected credit losses, the guidance requires companies to apply a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will evaluate the impact on the consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (subtopic 815-40) that provides new guidance on the accounting for convertible debt instruments and contracts in an entity’s own equity. The guidance simplifies the accounting for convertible instruments by reducing the various accounting models that can require the instrument to be separated into a debt component and equity component or derivative component. Additionally, the guidance eliminated certain settlement conditions previously required to be able to classify a derivative in equity. The new guidance is effective on a modified or full retrospective basis for fiscal years beginning after December 15, 2023, including interim periods with those fiscal years. The Company will evaluate the impact on the consolidated financial statements.

The Company does not believe that any recently issued effective standards, or standards issued but not yet effective, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements.

Subsequent Events

The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration.

NOTE 4. STOCKHOLDERS’ EQUITY

Common Stock

On March 5, 2021, the Company completed an underwritten public offering in which the Company issued and sold 7,875,000 shares of the Company’s common stock at a price to the public of $8.00 per share (the "Offering"). Gross proceeds of the Offering were $63 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company and resulted in net proceeds of $59.0 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The underwriters retained a customary 30-day overallotment option to purchase up to 1,181,250 shares of common stock at the public offering price, less underwriting discounts and commission. The overallotment option was exercised on March 16, 2021 for 1,049,700 shares with gross proceeds of $8.4 million and net proceeds of $7.9 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Warrants

In June 2017, the Company issued stock purchase warrants to purchase 2,646,091 shares of common stock at an exercise price of $7.50 per share. The warrants, exercisable beginning six months and one day after issuance, have a 10-year term and are liability classified due to the holders’ right to require the Company to repurchase the warrants for cash upon certain deferred fundamental transactions ( “June 2017 Warrants”). See Note 7 for the fair value measurement of the warrant liability.

In connection with the entry into the Term Loan Facility, the Company issued to SVB and one of its affiliates stock purchase warrants to purchase an aggregate of 58,502 shares of the Company’s common stock at an exercise price of $6.41 per share. These warrants are immediately exercisable, have a 10-year term, contain a cashless exercise provision, and are classified in equity.

In November 2020, the Company issued warrants to purchase 5,230,910 shares of common stock which have an exercise price of $4.31 per share, contain a cashless exercise provision, will expire five years from the date of issuance and are equity classified (the “November 2020 Warrants”).

Table of Contents

The following is a summary of warrant activity for the three months ended March 31, 2022:

Description	Outstanding 12/31/2021		Exercised		Outstanding 3/31/22		Exercise Price		Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
June 2017 Warrants		2,457,501		-		2,457,501	$	7.50		5.2	$	-
November 2020 Warrants		4,109,344		-		4,109,344	$	4.31		3.6	$	-
SVB Warrants		29,251		-		29,251	$	6.41		5.4	$	-
Total Warrants		6,596,096		-		6,596,096	$	4.47		4.2		-

Stock Options

The following is a summary of stock option activity for the three months ended March 31, 2022:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2021		3,498,297		$	10.07		7.27	$	7,456
Granted		760,000			5.07
Exercised, cancelled, or forfeited		(69,291	)		14.44
Outstanding, March 31, 2022		4,189,006		$	9.08		7.64	$	946

Exercisable, March 31, 2022		2,116,338		$	10.75		6.1	$	629

On September 13, 2018, the Company’s stockholders approved the 2018 Incentive Plan (as amended from time to time, the “2018 Plan”). The 2018 Plan provides that the Company may grant equity interests to employees, consultants, and members of the Board of Directors in the form of incentive and nonqualified stock options, restricted stock and restricted stock units, stock appreciation rights and various other forms of stock-based awards. On November 10, 2020, the Company held its 2020 annual meeting of stockholders at which the Company’s stockholders approved an amendment to the 2018 Plan, to increase the number of shares of the Company’s common stock issuable under the 2018 Plan by 1,750,000 shares. On November 9, 2021, the Company held its 2021 annual meeting of stockholders at which the Company’s stockholders approved an amendment to the 2018 Plan to increase the number of shares of the Company’s common stock issuable under the 2018 Plan by 4,000,000 shares (the “Plan Amendment”). The Board of Directors of the Company previously approved the Plan Amendment on August 3, 2021, subject to stockholder approval. There are 7,000,000 shares authorized for issuance pursuant to the 2018 Plan, of which 3,669,650 shares are available for issuance under the 2018 Plan.

Prior to the approval of the 2018 Plan, the Company granted options to employees, directors, advisors, and consultants from two former plans – the Old PLx Omnibus Stock Option Plan and the Dipexium 2013 Equity Incentive Plan (the “Prior Plans”). Upon the adoption of the 2018 Plan, the Prior Plans were frozen, and no new awards can be issued pursuant to the Prior Plans. The Company is no longer authorized to grant awards under these two plans.

The Company granted 760,000 options during the three months ended March 31, 2022 with an aggregate fair value of $2.7 million calculated using the Black-Scholes model on the grant date. Variables used in the Black-Scholes model include: (1) discount rate ranging from 1.6% - 1.9%, (2) expected life of 6 years, (3) expected volatility of 82%, and (4) zero expected dividends. As of March 31, 2022, the Company had $9.0 million in unamortized expense related to unvested options which is expected to be expensed over a weighted average of 2.2 years.

During the three months ended March 31, 2022 and 2021, the Company recorded $1.1 million and $0.6 million, respectively, in total stock-based compensation expense related to the stock options. Substantially all stock-based compensation expense is classified as selling, marketing and administrative expenses in the accompanying unaudited consolidated statements of operations.

NOTE 5. COMMITMENTS AND CONTINGENCIES

Lease Agreements

The Company presently leases office space under operating lease agreements, expiring in September 2023, and June 2024. The office leases require the Company to pay for its maintenance, and insurance. Rental expense under these agreements was $0.03 million and $0.09 million for the three months ended March 31, 2022 and 2021, respectively.

Operating lease ROU assets are included in right of use assets in the Company's unaudited consolidated balance sheets. Operating lease liabilities are included in other current and non-current liabilities in the Company’s unaudited consolidated balance sheets.

Table of Contents

All the Company’s existing leases as of March 31, 2022 are classified as operating leases and have a weighted average remaining lease term of 1.9 years. Certain of the Company’s existing leases have fair value renewal options, none of which the Company considers certain of being exercised or included in the minimum lease term. The discount rate used in the calculation of the Company’s lease liability ranges from 7.25% to 9.50%.

A maturity analysis of the Company’s operating leases follows:

Future undiscounted cash flows:
2022	$	98,756
2023		113,823
2024		30,132
Total		242,711

Discount factor		(19,851	)
Lease liability		222,860
Current lease liability		(117,131	)
Non-current lease liability	$	105,729

Purchase Commitments

As of March 31, 2022, the Company had entered into media and advertising commitments for VAZALORE of $2.9 million which are expected to be paid during the second quarter of 2022.

The Company has supply agreements with its contract manufacturer and packager for VAZALORE which contain minimum annual purchase commitments that started in 2021 and continue through 2025. The minimum annual purchase commitments are intended to ensure that manufactured product is available when required to enable the Company to meet its expected market demand for VAZALORE.

NOTE 6. FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received in the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company has categorized all investments recorded at fair value based upon the level of judgment associated with the inputs used to measure their fair value.

Hierarchical levels, directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

	●	Level 1: Quoted prices in active markets for identical assets or liabilities that the organization has the ability to access at the reporting date.
	●	Level 2: Inputs other than quoted prices included in Level 1, which are either observable or that can be derived from or corroborated by observable data as of the reporting date.
	●	Level 3: Inputs include those that are significant to the fair value of the asset or liability and are generally less observable from objective resources and reflect the reporting entity’s subjective determinations regarding the assumptions market participants would use in pricing the asset or liability.

The Company’s financial instruments (cash and cash equivalents, receivables, and accounts payable) are carried in the consolidated balance sheet at cost, which reasonably approximates fair value based on their short-term nature. The Company’s warrant liability is recorded at fair value, with changes in fair value being reflected in the statements of operations for the period of change.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

The June 2017 Warrants contain certain cash settlement features and, accordingly, the Company considered them to be liabilities and accounted for them at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a binomial asset pricing model that consisted of a conditional probability weighted expected return method that values the Company’s equity securities assuming various possible future outcomes to estimate the allocation of value within one or more of the scenarios. Using this method, unobservable inputs included the Company’s equity value, expected timing of possible outcomes, risk free interest rates and stock price volatility. Variables used at March 31, 2022 include: (1) the Company stock price of $4.04, (2) the risk-free rate of 2.42%, (3) remaining expected life of 5.2 years, and (4) expected volatility of 82%.

Table of Contents

The Series A Preferred Stock and the Series B Preferred Stock both contain a contingent put option and, accordingly, the Company considered the put options to be liabilities and accounted for them at fair value using Level 3 inputs. The Company determined the fair value of these liabilities was de minimis at issuance and as of March 31, 2022, due to the remote possibly of its occurrence, a Level 3 unobservable input.

The following table sets forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the three months ended March 31, 2022:

Description

Balance at

December 31, 2021

Established

in 2022

Change in

Fair Value

Balance at

March 31, 2022

Warrant liability

12,818

(7,408

)

5,410

The following table identifies the carrying amounts of such liabilities at March 31, 2022 and December 31, 2021:

Description	Level 1		Level 2		Level 3		Total

Warrant liability	$	-	$	-	$	5,410	$	5,410
Balance at March 31, 2022	$	-	$	-	$	5,410	$	5,410

Description	Level 1		Level 2		Level 3		Total

Warrant liability	$	-	$	-	$	12,818	$	12,818
Balance at December 31, 2021	$	-	$	-	$	12,818	$	12,818

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets or liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets or liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and goodwill, at fair value on a non-recurring basis when they are deemed to be impaired. No such impairment was recognized during the three months ended March 31, 2022 and 2021.

NOTE 7. SUBSEQUENT EVENTS

The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration and none were noted.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements in this Quarterly Report on Form 10-Q (the “Quarterly Report”) that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of pre-clinical studies, clinical trials and studies, research and development expenses, cash expenditures, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to conduct and obtain successful results from ongoing clinical trials, commercialize our technology, obtain regulatory approval for our product candidates, contract with third parties to adequately test and manufacture our proposed therapeutic products, protect our intellectual property rights and obtain additional financing to continue our development efforts. We do not undertake to update any of these forward-looking statements or to announce the results of any revisions to these forward-looking statements except as required by law.

We urge you to read this entire Quarterly Report, including the “Risk Factors” referenced under Part II. Item 1A, the financial statements, and related notes. The information contained herein is current as of the date of this Quarterly Report (March 31, 2022), unless another date is specified. We prepare our interim financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Our financials and results of operations for the three months ended March 31, 2022 and 2021 are not necessarily indicative of our prospective financial condition and results of operations for the pending full fiscal year ending December 31, 2022. The interim financial statements presented in this Quarterly Report as well as other information relating to the Company contained in this Quarterly Report should be read in conjunction and together with the reports, statements and information filed by us with the United States Securities and Exchange Commission (the “SEC”).

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is provided in addition to the accompanying financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows.

Overview

We are a commercial-stage drug delivery platform technology company focused on improving how and where APIs are absorbed in the GI tract via our clinically validated and patent protected PLxGuard™ technology. We believe this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach injury associated with certain drugs.

VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach lining. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin.

Our commercialization strategy targets the OTC market, taking advantage of the existing distribution channels for aspirin. We market VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Our product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform that may be developed, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase 1 clinical stage. We are also screening additional compounds outside the NSAID category for possible development using our PLxGuard drug delivery platform.

Critical Accounting Policies

Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Note 3 of the Notes to the Consolidated Financial Statements (unaudited) included elsewhere herein describes the significant accounting policies used in the preparation of the financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.

A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: (1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the financial statements as soon as they became known. Based on a critical assessment of our accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that our financial statements are fairly stated in accordance with U.S. GAAP and present a meaningful presentation of our financial condition and results of operations. We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation of our consolidated financial statements:

Table of Contents

Impact of COVID-19 Pandemic on Financial Statements

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses.

In response to COVID-19, the Company has not experienced a significant disruption or delay in the development, manufacturing or sale of VAZALORE, and has not otherwise experienced any significant negative impact on its financial condition, results of operations or cash flows. However, the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company has not experienced any significant negative impact on its March 31, 2022 unaudited consolidated financial statements related to COVID-19.

Use of Estimates

The preparation of our unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, the impairment assessment of goodwill, the fair value of warrant liability, the fair value of stock-based compensation, allowance for inventory obsolescence, and deferred taxes and associated valuation allowance. Actual results could differ from those estimates.

Fair Value Measurements

Hierarchical levels, directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

	●	Level 1: Quoted prices in active markets for identical assets or liabilities that the organization has the ability to access at the reporting date.
	●	Level 2: Inputs other than quoted prices included in Level 1, which are either observable or that can be derived from or corroborated by observable data as of the reporting date.
	●	Level 3: Inputs include those that are significant to the fair value of the asset or liability and are generally less observable from objective resources and reflect the reporting entity’s subjective determinations regarding the assumptions market participants would use in pricing the asset or liability.

Revenue Recognition

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit.

The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 mg and 325 mg doses in the third quarter of 2021 and recognizes revenue when control of a promised good is transferred to a customer in an amount that reflects consideration that the Company expects to be entitled to in exchange for that good. This occurs either when the finished goods are delivered to the customer or when a product is picked up by the customer or the customer’s carrier. The Company recognized total revenue from sales of VAZALORE of $2.1 million with $1.7 million or 79% of net sales for the 81 mg dose and $0.4 million or 21% of net sales for the 325 mg dose for the three months ended March 31, 2022.

Table of Contents

Research and Development Expenses

Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of direct and indirect costs associated with manufacturing and regulatory activities, and include fees paid to various entities that perform research-related services for the Company.

Stock-Based Compensation

The Company recognizes expense in the consolidated statements of operations for the fair value of all stock-based compensation to key employees, nonemployee directors and advisors, generally in the form of stock options. The Company uses the Black-Scholes option valuation model to estimate the fair value of stock options on the grant date. Compensation cost is amortized on a straight-line basis over the vesting period for each respective award. The Company accounts for forfeitures as they occur.

Adopted Accounting Guidance

For a discussion of significant accounting guidance recently adopted or unadopted accounting guidance that has the potential of being significant, see Note 3 of the Notes to the Unaudited Consolidated Financial Statements included elsewhere herein.

Non-GAAP Financial Measures

We prepare and publicly release quarterly unaudited financial statements prepared in accordance with generally accepted accounting principles (“GAAP”). We also disclose and discuss certain non-GAAP financial measures in our public releases, investor conference calls and filings with the SEC. The non-GAAP financial measures that we disclose include adjusted non-GAAP loss attributable to common stockholders and adjusted non-GAAP net loss per common share. Non-GAAP net loss per share is defined as net loss per share excluding the change in the fair value of warrant liability and dividends related to our preferred stock.

We consider adjusted non-GAAP net loss and adjusted non-GAAP net loss per basic and diluted earnings per share to be an important financial indicator of our operating performance, providing investors and analysts with a useful measure of operating results unaffected by the impact on the financial statements of the volatility of the change in the fair value of the warrant liability and non-cash and non-recurring dividends on our preferred stock. Management uses adjusted non-GAAP net loss and adjusted non-GAAP net loss per share when analyzing our performance. Adjusted non-GAAP net loss and adjusted non-GAAP net loss per share should be considered in addition to, but not in lieu of net loss or net loss per share reported under GAAP.

A reconciliation of adjusted non-GAAP net loss per share to the most directly comparable GAAP finance measure is provided below.

	Three Months Ended March 31,
(in thousands, except share and per share data)	2022			2021

Net loss attributable to common stockholders - GAAP	$	(10,785	)	$	(11,862	)
Adjustments:
Change in fair value of warrant liability		(7,408	)		7,935
Preferred dividends		-			322

Adjusted non-GAAP net loss attributable to common stockholders	$	(18,193	)	$	(3,605	)

Adjusted non-GAAP net loss per common share - basic and diluted	$	(0.66	)	$	(0.22	)

Weighted average shares of common shares - basic and diluted		27,539,229			16,361,583

RESULTS OF OPERATIONS

Comparison of Three Months Ended March 31, 2022 and 2021

Revenue

Total revenues were $2.1 million for the three months ended March 31, 2022, compared to no revenue for the three months ended March 31, 2021, and reflected the launch of VAZALORE 81 mg and 325 mg dose strengths with initial distribution to U.S. retail channels in the third quarter of 2021. Net sales were led by the 81 mg dose strength (consisting of two SKUs), which represented 79% of total revenues in the first quarter of 2022.

Gross Profit

Gross profit for the three months ended March 31, 2022 of $0.9 million. Gross margin of 44% reflects outsourced manufacturing and packaging costs, shipping costs, quality assurance and royalties. Gross profit from our 325 mg dose is lower than our 81 mg dose due to the proportionally higher use of raw materials and the manufacturing of smaller batch sizes, notwithstanding a list price that is equal to the 81 mg 30 count bottle. We are working on expanding our manufacturing capacity by the end of 2022 which we expect will improve gross margin.

Table of Contents

Operating Expenses

Total operating expenses were $19.1 million for the three months ended March 31, 2022, increased from operating expenses of $3.6 million for the three months ended March 31, 2021and reflected the promotional activities and associated expenses for the continued commercial launch of VAZALORE. Operating expenses for the three months ended March 31, 2022 and 2021 were as follows:

	Three Months Ended March 31,				Increase (Decrease)
	2022		2021			$		%
	(in thousands, except percentages)
Operating Expenses
Research and development expenses	$	654	$	959	$	(305	)		(32	)%
Selling, marketing and administrative expenses		18,456		2,636		15,820			600	%
Total operating expenses	$	19,110	$	3,595	$	15,515			432	%

Research and Development Expenses

Research and development expense consists of expenses incurred while performing research and development activities to discover, develop, or improve potential product candidates we seek to develop. This includes conducting preclinical studies and clinical trials, manufacturing and other development efforts, and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expenses primarily consist of (i) direct and indirect costs associated with specific projects and manufacturing activities, and (ii) fees paid to various entities that perform research related services for us.

Research and development expenses were $0.7 million for the three months ended March 31, 2022 compared to $1.0 million for the three months ended March 31, 2021. The decrease reflects the non-recurrence of the prior year costs for pre-commercial manufacturing-related activities such as validation and optimization work for VAZALORE.

Selling, Marketing and Administrative Expenses

SM&A expenses include costs related to functions such as sales, marketing, corporate management, insurance, and legal costs. Broker commissions are incurred and expensed as SM&A costs in the underlying consolidated statements of operations when the underlying sales take place. SM&A expenses also include costs for advertising (excluding the costs of cooperative advertising programs, which are reflected in net sales), contract field force, and consumer promotion costs (such as on-shelf advertisements and displays). SM&A costs are expensed as incurred.

Selling, marketing and administrative expenses totaled $18.5 million for the three months ended March 31, 2022, compared to $2.6 million for the three months ended March 31, 2021. The increase primarily reflects higher sales and marketing expenses related to the VAZALORE launch. In the third quarter of 2021, a cardiovascular specialty field force and a national media television campaign were launched to raise awareness amongst healthcare professionals and consumers. Non-cash stock-based compensation was $1.1 million in the current period versus $0.6 million in the prior year period.

Other income (expense), net

Other income (expense), net totaled $7.4 million of other income and $7.9 million of other expense for the three months ended March 31, 2022 and 2021, respectively. The variance is largely attributable to the non-cash change in fair value of warrant liability primarily due to the fluctuation of the price of the Company’s common stock.

LIQUIDITY AND CAPITAL RESOURCES

Financial Condition

The following table summarizes the primary uses and sources of cash for the periods indicated:

	Three Months Ended March 31,
	2022			2021

Net cash used in operating activities	$	(16,893	)	$	(4,282	)
Net cash provided by financing activities	$	-		$	66,257

Table of Contents

Net Cash Used in Operating Activities

Net cash used in operating activities of $16.9 million and $4.3 million for the three months ended March 31, 2022 and 2021, respectively, is higher in 2022 due to the combination of higher operating expenses primarily related to sales and marketing and increased inventory purchases to support the continued launch of VAZALORE, offset by the timing of expense payments.

Net Cash Provided by Financing Activities

Net cash provided by financing activities totaled $0 during the three months ended March 31, 2022 compared to $66.3 million during the three months ended March 31, 2021. The prior year period reflects net proceeds from the Offering (as defined in Note 4 of the Notes to the Consolidated Financial Statements (unaudited)).

Future Liquidity and Capital Needs

Even though we are generating revenue, we may never achieve profitability, and even if we do achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline. Because of the numerous risks and uncertainties associated with developing biopharmaceutical products, we are unable to predict the extent of any future losses or when, if ever, we will become profitable. Although the achievement of future profitable operations and the ability to generate sufficient cash from operations is uncertain at this time, based on the Company's plans, the Company has adequate cash on hand at March 31, 2022 to fund its obligations for at least one year from the date these financial statements were issued, which mitigates the substantial doubt consideration.

Our future capital requirements will remain dependent upon a variety of factors, including cash flow from operations, the ability to increase sales, increasing our gross profits from current levels, reducing sales and administrative expenses as a percentage of net sales, continued development of customer relationships, and our ability to market our new products successfully. However, based on our results from operations, we may determine that we need to obtain additional financing in the future to further our commercialization plan. We may obtain additional financing through public or private equity offerings, debt financings (including related-party financings), a credit facility or strategic collaborations. Additional financing may not be available to us when we need it or it may not be available to us on favorable terms, if at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We currently have no understandings, commitments or agreements relating to any of these types of transactions. If we are unable to raise additional funds when needed, we may be required to sell or license our technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this item as we are considered a smaller reporting company, as defined in Section 229.10(f)(1) of Regulation S-K.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Based on an evaluation under the supervision, and with the participation, of the Company’s management, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were effective as of March 31, 2022 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that many of our employees are working remotely. We are continually monitoring and assessing the COVID-19 pandemic situation on our internal controls to minimize the impact on their design and operating effectiveness.

Table of Contents

Inherent Limitations Over Internal Controls

The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. The Company’s internal control over financial reporting includes those policies and procedures that:

●

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets;

●

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that the Company’s receipts and expenditures are being made only in accordance with authorizations of the Company’s management and directors; and

●

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Management, including the Company’s principal executive officer and principal financial officer, does not expect that the Company’s internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls with respect to future periods is subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time we are party to legal proceedings that we believe to be ordinary, routine litigation incidental to the business of present or former operations. It is management’s opinion, based on the advice of counsel, that the ultimate resolution of such litigation will not have a material adverse effect on our financial condition, results of operations or cash flows.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report, please carefully consider the risk factors described in our most recent Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2021, under the heading “Part I – Item 1A. Risk Factors.” The risks described are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that our management currently deems to be immaterial, also may adversely affect our business, financial condition, and/or operating results. There have been no material changes to those risk factors since their disclosure in our most recent Annual Report on Form 10-K, as amended.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Quarterly Report.

Table of Contents

INDEX TO EXHIBITS

Number	Description

31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2	Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1	Certification of the Principal Executive Officer and Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101	The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL: (i) Consolidated Balance Sheets (unaudited), (ii) Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Changes in Series A and Series B Convertible Preferred Stock and Stockholders’ Equity (unaudited), (iv) Consolidated Statements of Cash Flows (unaudited), and (v) Notes to Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.

104	Cover Page Interactive Data File (Embedded within the Inline XBRL and included in Exhibit 101).

Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PLX PHARMA INC.

Date: May 13, 2022		/s/ Natasha Giordano
		By: Natasha Giordano
		Title: President and Chief Executive Officer (Principal Executive Officer)

		/s/ Rita O’Connor
		By: Rita O’Connor
		Title: Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex_364549.htm EXHIBIT 31.1 ex_364549.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Natasha Giordano, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of PLx Pharma Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d– 15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2022		/s/ Natasha Giordano
		Natasha Giordano President and
		Chief Executive Officer (principal executive officer)

EX-31.2 3 ex_364550.htm EXHIBIT 31.2 ex_364550.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rita O’Connor, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of PLx Pharma Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2022		/s/ Rita O’Connor
		Rita O’Connor
		Chief Financial Officer (principal financial officer)

EX-32.1 4 ex_364551.htm EXHIBIT 32.1 ex_364551.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of PLx Pharma Inc. (the "Company") for the quarterly period ended March 31, 2022 (the "Report") as filed with the Securities and Exchange Commission on the date hereof, the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify that, to such officer’s knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Dated: May 13, 2022		/s/ Natasha Giordano
		Natasha Giordano
		President and Chief Executive Officer (principal executive officer)

Dated: May 13, 2022		/s/ Rita O’Connor
		Rita O’Connor
		Chief Financial Officer (principal financial officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 5 plxp-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flow (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Background and Organization link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Liquidity link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 4 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 5 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 6 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 2 - Liquidity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 4 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Stockholders' Equity - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 6 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 plxp-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 plxp-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 plxp-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Note To Financial Statement Details Textual Significant Accounting Policies us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2023 Note 3 - Summary of Significant Accounting Policies us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2024 Note 4 - Stockholders' Equity Note 5 - Commitments and Contingencies Note 6 - Fair Value Measurements Subsequent Events, Policy [Policy Text Block] Note 3 - Summary of Significant Accounting Policies - Inventory (Details) Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) NON-CURRENT LIABILITIES Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details) Note 4 - Stockholders' Equity - Stock Option Activity (Details) Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details) Change in fair value of warrant liability Change in fair value of warrant liability Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details) Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock-based compensation Notes To Financial Statements us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear 2022 us-gaap_LiabilitiesCurrent TOTAL CURRENT LIABILITIES Notes To Financial Statements [Abstract] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) Other current liabilities Earnings Per Share, Policy [Policy Text Block] Amortization of debt discounts and issuance costs OPERATING EXPENSES: Share-Based Payment Arrangement, Option, Activity [Table Text Block] us-gaap_LiabilitiesFairValueDisclosure Balance Depreciation and amortization us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Exercisable, weighted average exercise price (in dollars per share) us-gaap_AssetsCurrent TOTAL CURRENT ASSETS Exercisable, weighted average remaining contractual term (Year) NON-CURRENT ASSETS Exercisable, aggregate intrinsic value Stockholders' Equity Note Disclosure [Text Block] Exercisable, number of units (in shares) Outstanding, weighted average remaining contractual term (Year) Outstanding, aggregate intrinsic value Advertising Cost [Policy Text Block] Interest income (expense), net Common stock; $0.001 par value; 100,000,000 shares authorized; 27,539,229 shares issued and outstanding at March 31, 2022 and December 31, 2021 Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price, beginning balance (in dollars per share) Outstanding, weighted average exercise price, balance (in dollars per share) Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Accounts payable and accrued liabilities Common stock, shares issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Exercised, cancelled, or forfeited, weighted average exercise price (in dollars per share) Common stock, par value (in dollars per share) Granted, weighted average exercise price (in dollars per share) Revenue from Contract with Customer [Policy Text Block] Inventory, net Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, number of units, balance (in shares) Outstanding, number of units, balance (in shares) Product and Service [Domain] Statistical Measurement [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Exercised, cancelled, or forfeited, number of units (in shares) Series B Convertible Preferred Stock [Member] Related to Series B Convertible Preferred Stock. Preferred stock; $0.001 par value; 930,000 shares authorized; none issued and outstanding at March 31, 2022 and December 2021 Preferred stock, shares issued (in shares) Interest us-gaap_PolicyTextBlockAbstract Accounting Policies plxp_WorkingCapital Working Capital Represents the capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities. Preferred stock, shares authorized (in shares) us-gaap_InventoryNet Total Inventory us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Preferred stock, par value (in dollars per share) Warrants (in shares) TOTAL REVENUES Revenue from Contract with Customer, Including Assessed Tax Fair Value, Inputs, Level 3 [Member] Stock Options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) Convertible Preferred Stock (in shares) Fair Value Hierarchy and NAV [Domain] NON-CASH INVESTING AND FINANCING TRANSACTIONS us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_IncomeTaxesPaidNet Income taxes Fair Value Hierarchy and NAV [Axis] Accrued bonuses Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements and for severances. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). CURRENT LIABILITIES Product [Member] us-gaap_Assets TOTAL ASSETS SUPPLEMENTAL INFORMATION Plan Name [Axis] Plan Name [Domain] plxp_IncreaseDecreaseInBonusesAndSeverances Accrued bonuses The increase (decrease) during the period in bonuses and severances. VAZALORE [Member] Represents Vazalore. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_OperatingLeaseExpense Operating Lease, Expense CASH FLOWS FROM OPERATING ACTIVITIES us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) plxp_ReservesForSalesReturnsAndConsumerAndTradePromotionObligations Reserves for Sales Returns and Consumer and Trade Promotion Obligations Represents amount of reserves for sales returns and consumer and trade promotion obligations. Statement [Line Items] Accounts receivable Financing Represents financing, value. Financing (in shares) Represents financing, shares. REVENUES: plxp_IncreaseDecreaseInInterestPayableNetExcludingRelatedParties Accrued interest The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties excluding related parties for interest earned on loans or credit extended to the reporting entity. Additional paid-in capital STOCKHOLDERS' EQUITY us-gaap_NonoperatingIncomeExpense TOTAL OTHER INCOME (EXPENSE) Business Description and Basis of Presentation [Text Block] Award Type [Domain] us-gaap_PreferredStockDividendsIncomeStatementImpact Preferred dividends Convertible preferred stock, liquidation value CURRENT ASSETS Preferred stock Convertible preferred stock, shares authorized (in shares) Fair Value Disclosures [Text Block] Convertible preferred stock, shares issued (in shares) Award Type [Axis] Convertible preferred stock, shares outstanding (in shares) Net loss Net income (loss) NET LOSS us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance Media and Advertising Commitments [Member] Rerpesents the media and advertising commitments. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Inventory, Policy [Policy Text Block] Convertible preferred stock, par value (in dollars per share) us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Over-Allotment Option [Member] Employees [Member] Represents the employees of the company. us-gaap_Liabilities TOTAL LIABILITIES us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss OPERATING LOSS Share-Based Payment Arrangement, Option [Member] OTHER INCOME (EXPENSE): us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities plxp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Prepaid expenses and other current assets Costs of sales us-gaap_GrossProfit GROSS PROFIT Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Commitments and Contingencies Disclosure [Text Block] Property and equipment, net us-gaap_DerivativeLiabilities Liability Goodwill plxp_ProceedsFromIssuanceOfCommonStockNetOfDiscountsAndIssuanceCosts Proceeds from Issuance of Common Stock, Net of Discounts and Issuance Costs The cash inflow from the issuance of common stock net of discounts and stock issuance costs. Aggregate Intrinsic Value Represents the aggregate intrinsic value related to class of warrant or right. Remaining Contractual Term (Year) Represents class of warrant or right, remaining contractual term. Scenario [Domain] Forecast [Member] Retained Earnings [Member] Other current and long-term liabilities us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Title of Individual [Domain] Title of Individual [Axis] Scenario [Axis] us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Accounts payable and accrued liabilities Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] Income taxes Equity Components [Axis] Equity Component [Domain] Warrants exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right [Axis] Other Current Liabilities [Member] Class of Warrant or Right [Domain] Other Noncurrent Liabilities [Member] Warrants outstanding (in shares) us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest LOSS BEFORE INCOME TAXES us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_OperatingExpenses TOTAL OPERATING EXPENSES VAZALORE 81 mg Dose [Member] Related to VAZALORE 81 mg Dose. VAZALORE 325 mg Dose [Member] Related to VAZALORE 81 mg Dose. Cash and cash equivalents plxp_ClassOfWarrantOrRightTerm Class of Warrant or Right, Term (Year) The exercisable period of time after issuance for warrants and rights, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense Public Offering [Member] The concurrent sale of stock by a private company to the public. us-gaap_RepaymentsOfLongTermDebt Repayments of long-term debt us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value Balance Sheet Location [Axis] Balance Sheet Location [Domain] EX-101.PRE 9 plxp-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 picture1.jpg begin 644 picture1.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2022	May 10, 2022
Document Information [Line Items]
Entity Central Index Key	0001497504
Entity Registrant Name	PLx Pharma Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-36351
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4995704
Entity Address, Address Line One	9 Fishers Lane, Suite E
Entity Address, City or Town	Sparta
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07871
City Area Code	973
Local Phone Number	409-6541
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PLXP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,539,229

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 52,499	$ 69,392
Accounts receivable	698	634
Inventory, net	3,839	2,458
Prepaid expenses and other current assets	712	992
TOTAL CURRENT ASSETS	57,748	73,476
NON-CURRENT ASSETS
Property and equipment, net	828	858
Right of use assets	204	230
Goodwill	2,061	2,061
Security deposit	17	17
TOTAL ASSETS	60,858	76,642
CURRENT LIABILITIES
Accounts payable and accrued liabilities	12,716	10,600
Accrued bonuses	394	1,163
Other current liabilities	120	116
TOTAL CURRENT LIABILITIES	13,230	11,879
NON-CURRENT LIABILITIES
Warrant liability	5,410	12,818
Accrued dividends	129	129
Other liabilities	106	136
TOTAL LIABILITIES	18,875	24,962
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 930,000 shares authorized; none issued and outstanding at March 31, 2022 and December 2021	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 27,539,229 shares issued and outstanding at March 31, 2022 and December 31, 2021	28	28
Additional paid-in capital	185,000	183,912
Accumulated deficit	(159,059)	(148,274)
TOTAL STOCKHOLDERS' EQUITY	25,969	35,666
TOTAL LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	60,858	76,642
Series A Convertible Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock	13,708	13,708
Series B Convertible Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock	2,306	2,306
Commitments and contingencies

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	930,000	930,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,539,229	27,539,229
Common stock, shares outstanding (in shares)	27,539,229	27,539,229
Series A Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (in shares)	45,000	45,000
Convertible preferred stock, shares issued (in shares)	12,642	12,642
Convertible preferred stock, shares outstanding (in shares)	12,642	12,642
Convertible preferred stock, liquidation value	$ 12,642,000	$ 12,642,000
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized (in shares)	25,000	25,000
Convertible preferred stock, shares issued (in shares)	2,364	2,364
Convertible preferred stock, shares outstanding (in shares)	2,364	2,364
Convertible preferred stock, liquidation value	$ 2,492,722	$ 2,492,722

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUES:
TOTAL REVENUES	$ 2,083	$ 0
Costs of sales	1,169	0
GROSS PROFIT	914	0
OPERATING EXPENSES:
Research and development	654	959
Selling, marketing and administrative	18,456	2,636
TOTAL OPERATING EXPENSES	19,110	3,595
OPERATING LOSS	(18,196)	(3,595)
OTHER INCOME (EXPENSE):
Interest income (expense), net	3	(10)
Change in fair value of warrant liability	7,408	(7,935)
TOTAL OTHER INCOME (EXPENSE)	7,411	(7,945)
LOSS BEFORE INCOME TAXES	(10,785)	(11,540)
Income taxes	0	0
NET LOSS	(10,785)	(11,540)
Preferred dividends	0	(322)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (10,785)	$ (11,862)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.39)	$ (0.73)
Weighted average shares of common shares, basic and diluted (in shares)	27,539,229	16,361,583
Product [Member]
REVENUES:
TOTAL REVENUES	$ 2,083	$ 0

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Series B Preferred Stock [Member] Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	15,000			8,000			13,911,633
Balance at Dec. 31, 2020	$ 13,662			$ 7,723			$ 14	$ 91,203	$ (102,149)	$ (10,932)
Stock-based compensation expense								573		573
Net income (loss)									(11,540)	(11,540)
Preferred stock - declared dividends		$ (217)	$ (217)		$ (105)	$ (105)
Financing (in shares)							8,924,700
Financing							$ 9	66,873		66,882
Balance (in shares) at Mar. 31, 2021	15,000			8,000			22,836,333
Balance at Mar. 31, 2021	$ 13,662			$ 7,723			$ 23	158,327	(113,689)	44,661
Balance (in shares) at Dec. 31, 2021	12,642						27,539,229
Balance at Dec. 31, 2021	$ 13,708						$ 28	183,912	(148,274)	35,666
Stock-based compensation expense								1,088		1,088
Net income (loss)									(10,785)	(10,785)
Balance (in shares) at Mar. 31, 2022	12,642			2,364			27,539,229
Balance at Mar. 31, 2022	$ 13,708			$ 2,306			$ 28	$ 185,000	$ (159,059)	$ 25,969

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (10,785)	$ (11,540)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	30	27
Stock-based compensation	1,088	573
Amortization of right of use assets	26	77
Amortization of debt discounts and issuance costs	0	3
Change in fair value of warrant liability	(7,408)	7,935
Loss on sale of property and equipment	0	28
Changes in operating assets and liabilities
Accounts receivable	(64)	0
Inventory	(1,381)	0
Prepaid expenses and other assets	280	138
Accounts payable and accrued liabilities	2,116	100
Accrued bonuses	(769)	(938)
Accrued interest	0	(597)
Other current and long-term liabilities	(26)	(88)
Net cash used in operating activities	(16,893)	(4,282)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stock	0	66,882
Repayments of long-term debt	0	(625)
Net cash provided by financing activities	0	66,257
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(16,893)	61,975
Cash and cash equivalents, beginning of period	69,392	22,449
Cash and cash equivalents, end of period	52,499	84,424
SUPPLEMENTAL INFORMATION
Income taxes	0	0
Interest	0	602
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Preferred stock dividends	$ 0	$ 322

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Background and Organization

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

NOTE 1. BACKGROUND AND ORGANIZATION

Business Operations

Impact of COVID-19 Pandemic on Financial Statements

The Company has not experienced any significant negative impact on its March 31, 2022 unaudited consolidated financial statements related to COVID-19.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Liquidity

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

NOTE 2. LIQUIDITY

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting and Principles of Consolidation

The accompanying consolidated financial statements are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The December 31, 2021 consolidated balance sheet included herein was derived from audited consolidated financial statements as of that date. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously filed in its Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, the unaudited interim consolidated financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2022 and the results of operations for the three months ended March 31, 2022 and 2021.

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, PLx Opco Inc. All significant intercompany balances and transactions have been eliminated within the unaudited consolidated financial statements.

Use of Estimates

The preparation of our unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, the fair value of warrant liability, the fair value of stock-based compensation, trade promotional allowances, allowance for inventory obsolescence, and deferred taxes and associated valuation allowance. Actual results could differ from those estimates.

Inventory

Inventory is stated at the lower of cost or net realizable value, using the first-in first-out method based on actual costs. Inventory as of March 31, 2022 and December 31, 2021 was comprised of the following:

Description

March 31,
2022

December

31, 2021

(in thousands)

Raw Materials
$ 164 $ 132

Work-in-Progress
1 338

Finished Goods
3,674 1,988

Total Inventory
$ 3,839 $ 2,458

The Company regularly reviews inventory quantities on hand and assesses the need for an allowance for obsolescence based on estimates of net realizable value. The allowance for obsolete inventory as of March 31, 2022 and December 31, 2021 was not material.

Revenue Recognition

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit.

The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 mg and 325 mg doses in the third quarter of 2021 and recognizes revenue, at a point in time, when control of a promised good is transferred to a customer in an amount that reflects consideration that the Company expects to be entitled to in exchange for that good. This occurs either when the finished goods are received by the customer or when a product is picked up by the customer or the customer’s carrier. The Company recognized total revenue from sales of VAZALORE of $2.1 million with $1.7 million or 79% of net sales for the 81 mg dose and $0.4 million or 21% of net sales for the 325 mg dose for the three months ended March 31, 2022.

Nature of Goods and Services

The Company generates revenue from the sale of its VAZALORE products through a broad distribution platform that includes drugstores, mass merchandisers, grocery stores, and e-commerce channels, all of which sell its products to consumers. Finished goods products are typically shipped FOB destination and accordingly, the Company recognizes revenue upon delivery to the customer or pick-up by the customer’s carrier.

Satisfaction of Performance Obligations

The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. The Company had no unsatisfied performance obligations or deferred revenue as of March 31, 2022.

Variable Consideration

Provisions for certain customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales, based on an estimate of future returns, and customer prompt payment discounts, redemption of coupons by consumers and trade promotional allowances paid to customers. These allowances cover extensive promotional activities, primarily comprised of cooperative advertising, slotting, coupons, periodic price reduction arrangements, and other in-store displays.

The reserves for sales returns and consumer and trade promotion obligations are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses trend experience and coupon redemption inputs to determine coupon reserve requirements and uses forecasted customer and sales organization inputs, and historical trend analysis for consumer brands to determine the reserves for other promotional activities and sales returns. The balance of reserves for sales returns and consumer and trade promotion obligations, reflected in the accompanying unaudited consolidated balance sheets in accounts payable and accrued liabilities, was $1.0 million as of March 31, 2022 and $1.3 million as of December 31, 2021.

Advertising

Advertising costs are expensed as they are incurred. The Company incurred advertising costs of $9.6 million during the three months ended March 31, 2022, which are included in SM&A expense in the unaudited consolidated statements of operations, and did not have any advertising costs during the three months ended March 31, 2021.

Income (Loss) Per Share

In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series A convertible preferred stock (the “Series A Preferred Stock”) and the Series B convertible preferred stock (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, collectively the “Preferred Stock”) contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the Preferred Stock and excludes the impact of those shares from the denominator.

In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the Preferred Stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock using the if-converted method.

Due to net losses, none of the participating securities nor potential dilutive securities had a dilutive impact during the three months ended March 31, 2022 and 2021.

The following table sets forth the potential dilutive securities:

March 31, 2022

March 31, 2021

Stock Options
4,189,006 3,033,047

Warrants
6,596,096 7,935,503

Convertible Preferred Stock
6,476,275 9,517,191

Total Potential Dilutive Shares
17,261,377 20,485,741

Recent Accounting Developments

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is designed to provide financial statement users with more information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. When determining such expected credit losses, the guidance requires companies to apply a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will evaluate the impact on the consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (subtopic 815-40) that provides new guidance on the accounting for convertible debt instruments and contracts in an entity’s own equity. The guidance simplifies the accounting for convertible instruments by reducing the various accounting models that can require the instrument to be separated into a debt component and equity component or derivative component. Additionally, the guidance eliminated certain settlement conditions previously required to be able to classify a derivative in equity. The new guidance is effective on a modified or full retrospective basis for fiscal years beginning after December 15, 2023, including interim periods with those fiscal years. The Company will evaluate the impact on the consolidated financial statements.

The Company does not believe that any recently issued effective standards, or standards issued but not yet effective, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements.

Subsequent Events

The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Stockholders' Equity

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE 4. STOCKHOLDERS’ EQUITY

Common Stock

Warrants

The following is a summary of warrant activity for the three months ended March 31, 2022:

Description	Outstanding 12/31/2021		Exercised		Outstanding 3/31/22		Exercise Price		Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
June 2017 Warrants		2,457,501		-		2,457,501	$	7.50		5.2	$	-
November 2020 Warrants		4,109,344		-		4,109,344	$	4.31		3.6	$	-
SVB Warrants		29,251		-		29,251	$	6.41		5.4	$	-
Total Warrants		6,596,096		-		6,596,096	$	4.47		4.2		-

Stock Options

The following is a summary of stock option activity for the three months ended March 31, 2022:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2021		3,498,297		$	10.07		7.27	$	7,456
Granted		760,000			5.07
Exercised, cancelled, or forfeited		(69,291	)		14.44
Outstanding, March 31, 2022		4,189,006		$	9.08		7.64	$	946

Exercisable, March 31, 2022		2,116,338		$	10.75		6.1	$	629

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

NOTE 5. COMMITMENTS AND CONTINGENCIES

Lease Agreements

A maturity analysis of the Company’s operating leases follows:

Future undiscounted cash flows:
2022	$	98,756
2023		113,823
2024		30,132
Total		242,711

Discount factor		(19,851	)
Lease liability		222,860
Current lease liability		(117,131	)
Non-current lease liability	$	105,729

Purchase Commitments

As of March 31, 2022, the Company had entered into media and advertising commitments for VAZALORE of $2.9 million which are expected to be paid during the second quarter of 2022.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value Measurements

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Fair Value Disclosures [Text Block]

NOTE 6. FAIR VALUE MEASUREMENTS

Hierarchical levels, directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

	●	Level 1: Quoted prices in active markets for identical assets or liabilities that the organization has the ability to access at the reporting date.
	●	Level 2: Inputs other than quoted prices included in Level 1, which are either observable or that can be derived from or corroborated by observable data as of the reporting date.
	●	Level 3: Inputs include those that are significant to the fair value of the asset or liability and are generally less observable from objective resources and reflect the reporting entity’s subjective determinations regarding the assumptions market participants would use in pricing the asset or liability.

Financial assets and liabilities measured at fair value on a recurring basis

The following table sets forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the three months ended March 31, 2022:

Description

Balance at

December 31, 2021

Established

in 2022

Change in

Fair Value

Balance at

March 31, 2022

Warrant liability

12,818

(7,408

)

5,410

The following table identifies the carrying amounts of such liabilities at March 31, 2022 and December 31, 2021:

Description	Level 1		Level 2		Level 3		Total

Warrant liability	$	-	$	-	$	5,410	$	5,410
Balance at March 31, 2022	$	-	$	-	$	5,410	$	5,410

Description	Level 1		Level 2		Level 3		Total

Warrant liability	$	-	$	-	$	12,818	$	12,818
Balance at December 31, 2021	$	-	$	-	$	12,818	$	12,818

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets or liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets or liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Subsequent Events

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Subsequent Events [Text Block]

NOTE 7. SUBSEQUENT EVENTS

XML 24 R14.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Accounting and Principles of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Inventory, Policy [Policy Text Block]

Inventory

Description	March 31, 2022		December 31, 2021
		(in thousands)
Raw Materials	$	164	$	132
Work-in-Progress		1		338
Finished Goods		3,674		1,988
Total Inventory	$	3,839	$	2,458

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Nature of Goods and Services

Satisfaction of Performance Obligations

Variable Consideration

Advertising Cost [Policy Text Block]

Advertising

Earnings Per Share, Policy [Policy Text Block]

Income (Loss) Per Share

Due to net losses, none of the participating securities nor potential dilutive securities had a dilutive impact during the three months ended March 31, 2022 and 2021.

The following table sets forth the potential dilutive securities:

	March 31, 2022		March 31, 2021
Stock Options		4,189,006		3,033,047
Warrants		6,596,096		7,935,503
Convertible Preferred Stock		6,476,275		9,517,191
Total Potential Dilutive Shares		17,261,377		20,485,741

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration.

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Inventory, Current [Table Text Block]

Description	March 31, 2022		December 31, 2021
		(in thousands)
Raw Materials	$	164	$	132
Work-in-Progress		1		338
Finished Goods		3,674		1,988
Total Inventory	$	3,839	$	2,458

Incremental Weighted Average Shares Attributable to Dilutive Effect [Table Text Block]

	March 31, 2022		March 31, 2021
Stock Options		4,189,006		3,033,047
Warrants		6,596,096		7,935,503
Convertible Preferred Stock		6,476,275		9,517,191
Total Potential Dilutive Shares		17,261,377		20,485,741

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 4 - Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Description	Outstanding 12/31/2021		Exercised		Outstanding 3/31/22		Exercise Price		Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
June 2017 Warrants		2,457,501		-		2,457,501	$	7.50		5.2	$	-
November 2020 Warrants		4,109,344		-		4,109,344	$	4.31		3.6	$	-
SVB Warrants		29,251		-		29,251	$	6.41		5.4	$	-
Total Warrants		6,596,096		-		6,596,096	$	4.47		4.2		-

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2021		3,498,297		$	10.07		7.27	$	7,456
Granted		760,000			5.07
Exercised, cancelled, or forfeited		(69,291	)		14.44
Outstanding, March 31, 2022		4,189,006		$	9.08		7.64	$	946

Exercisable, March 31, 2022		2,116,338		$	10.75		6.1	$	629

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Future undiscounted cash flows:
2022	$	98,756
2023		113,823
2024		30,132
Total		242,711

Discount factor		(19,851	)
Lease liability		222,860
Current lease liability		(117,131	)
Non-current lease liability	$	105,729

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Description

Balance at

December 31, 2021

Established

in 2022

Change in

Fair Value

Balance at

March 31, 2022

Warrant liability

12,818

(7,408

)

5,410

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

Description	Level 1		Level 2		Level 3		Total

Warrant liability	$	-	$	-	$	5,410	$	5,410
Balance at March 31, 2022	$	-	$	-	$	5,410	$	5,410

Description	Level 1		Level 2		Level 3		Total

Warrant liability	$	-	$	-	$	12,818	$	12,818
Balance at December 31, 2021	$	-	$	-	$	12,818	$	12,818

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 2 - Liquidity (Details Textual) $ in Millions	Mar. 31, 2022 USD ($)
Working Capital	$ 44.5
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance	52.5
Media and Advertising Commitments [Member]
Other Commitment, Total	$ 2.9

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax	$ 2,083	$ 0
Reserves for Sales Returns and Consumer and Trade Promotion Obligations	1,000		$ 1,300
Advertising Expense	9,600
VAZALORE [Member]
Revenue from Contract with Customer, Including Assessed Tax	2,100
VAZALORE 81 mg Dose [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 1,700
VAZALORE 81 mg Dose [Member] \| Product Concentration Risk [Member] \| Revenue, Product and Service Benchmark [Member]
Concentration Risk, Percentage	79.00%
VAZALORE 325 mg Dose [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 400
VAZALORE 325 mg Dose [Member] \| Product Concentration Risk [Member] \| Revenue, Product and Service Benchmark [Member]
Concentration Risk, Percentage	21.00%

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Raw Materials	$ 164	$ 132
Work-in-Progress	1	338
Finished Goods	3,674	1,988
Total Inventory	$ 3,839	$ 2,458

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock Options (in shares)	4,189,006	3,033,047
Warrants (in shares)	6,596,096	7,935,503
Convertible Preferred Stock (in shares)	6,476,275	9,517,191
Total Potential Dilutive Shares (in shares)	17,261,377	20,485,741

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 4 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions						3 Months Ended
	Nov. 09, 2021	Mar. 16, 2021	Mar. 05, 2021	Sep. 13, 2018	Aug. 09, 2017	Mar. 31, 2022	Mar. 31, 2021	Nov. 30, 2020	Jun. 30, 2017
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 4.47
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						760,000
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 9.0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						2 years 2 months 12 days
Share-Based Payment Arrangement, Expense						$ 1.1	$ 0.6
The 2018 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	4,000,000			1,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				7,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				3,669,650
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						760,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value						$ 2.7
The 2018 Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate						0.00%
The 2018 Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member] \| Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)						6 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate						82.00%
The 2018 Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate						1.60%
The 2018 Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate						1.90%
June 2017 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					58,502				2,646,091
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 6.41	$ 7.50			$ 7.50
Warrants and Rights Outstanding, Term (Year)									10 years
Class of Warrant or Right, Term (Year)					10 years
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			7,875,000
Shares Issued, Price Per Share (in dollars per share)			$ 8.00
Proceeds from Issuance of Common Stock			$ 63.0
Proceeds from Issuance of Common Stock, Net of Discounts and Issuance Costs			$ 59.0
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,049,700
Proceeds from Issuance of Common Stock		$ 8.4
Proceeds from Issuance of Common Stock, Net of Discounts and Issuance Costs		$ 7.9
Sale of Stock, Option to Purchase Shares (in shares)			1,181,250
November 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								5,230,910
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 4.31
Warrants and Rights Outstanding, Term (Year)								5 years

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Aug. 09, 2017	Jun. 30, 2017
Warrants outstanding (in shares)	6,596,096	6,596,096
Warrants exercised (in shares)	0
Warrants exercise price (in dollars per share)	$ 4.47
Remaining Contractual Term (Year)	4 years 2 months 12 days
Aggregate Intrinsic Value	$ 0
June 2017 Warrants [Member]
Warrants outstanding (in shares)	2,457,501	2,457,501
Warrants exercised (in shares)	0
Warrants exercise price (in dollars per share)	$ 7.50		$ 6.41	$ 7.50
Remaining Contractual Term (Year)	5 years 2 months 12 days
Aggregate Intrinsic Value	$ 0
November 2020 Warrants [Member]
Warrants outstanding (in shares)	4,109,344	4,109,344
Warrants exercised (in shares)	0
Warrants exercise price (in dollars per share)	$ 4.31
Remaining Contractual Term (Year)	3 years 7 months 6 days
Aggregate Intrinsic Value	$ 0
SVB Warrants [Member]
Warrants outstanding (in shares)	29,251	29,251
Warrants exercised (in shares)	0
Warrants exercise price (in dollars per share)	$ 6.41
Remaining Contractual Term (Year)	5 years 4 months 24 days
Aggregate Intrinsic Value	$ 0

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Stockholders' Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Outstanding, number of units, balance (in shares)	3,498,297
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 10.07
Outstanding, weighted average remaining contractual term (Year)	7 years 7 months 20 days	7 years 3 months 7 days
Outstanding, aggregate intrinsic value	$ 946	$ 7,456
Granted, number of units (in shares)	760,000
Granted, weighted average exercise price (in dollars per share)	$ 5.07
Exercised, cancelled, or forfeited, number of units (in shares)	(69,291)
Exercised, cancelled, or forfeited, weighted average exercise price (in dollars per share)	$ 14.44
Outstanding, number of units, balance (in shares)	4,189,006	3,498,297
Outstanding, weighted average exercise price, balance (in dollars per share)	$ 9.08	$ 10.07
Exercisable, number of units (in shares)	2,116,338
Exercisable, weighted average exercise price (in dollars per share)	$ 10.75
Exercisable, weighted average remaining contractual term (Year)	6 years 1 month 6 days
Exercisable, aggregate intrinsic value	$ 629

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022
Operating Lease, Expense	$ 30	$ 90
Operating Lease, Weighted Average Remaining Lease Term (Year)	1 year 10 months 24 days
Media and Advertising Commitments [Member]
Other Commitment, Total	$ 2,900
Media and Advertising Commitments [Member] \| Forecast [Member]
Other Commitment, Total			$ 2,900
Minimum [Member]
Lessee, Operating Lease, Discount Rate	7.25%
Maximum [Member]
Lessee, Operating Lease, Discount Rate	9.50%

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details) $ in Thousands	Mar. 31, 2022 USD ($)
2022	$ 98,756
2023	113,823
2024	30,132
Total	242,711
Discount factor	(19,851)
Lease liability	222,860
Other Current Liabilities [Member]
Current lease liability	(117,131)
Other Noncurrent Liabilities [Member]
Non-current lease liability	$ 105,729

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value Measurements (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Asset Impairment Charges, Total	$ 0	$ 0
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	4.04
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	2.42
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.2
Fair Value, Inputs, Level 3 [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	82

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details) - Derivative Warrant Liability [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Balance	$ 12,818
Established	0
Change in fair value	(7,408)
Balance	$ 5,410

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Balance	$ 5,410	$ 12,818
Derivative Warrant Liability [Member]
Liability	5,410	12,818
Fair Value, Inputs, Level 1 [Member]
Balance	0	0
Fair Value, Inputs, Level 1 [Member] \| Derivative Warrant Liability [Member]
Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Balance	0	0
Fair Value, Inputs, Level 2 [Member] \| Derivative Warrant Liability [Member]
Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Balance	5,410	12,818
Fair Value, Inputs, Level 3 [Member] \| Derivative Warrant Liability [Member]
Liability	$ 5,410	$ 12,818

XML 41 plxp20220331_10q_htm.xml IDEA: XBRL DOCUMENT 0001497504 2022-01-01 2022-03-31 0001497504 2022-05-10 0001497504 2022-03-31 0001497504 2021-12-31 0001497504 plxp:SeriesAConvertiblePreferredStockMember 2022-03-31 0001497504 plxp:SeriesAConvertiblePreferredStockMember 2021-12-31 0001497504 plxp:SeriesBConvertiblePreferredStockMember 2022-03-31 0001497504 plxp:SeriesBConvertiblePreferredStockMember 2021-12-31 0001497504 us-gaap:ProductMember 2022-01-01 2022-03-31 0001497504 us-gaap:ProductMember 2021-01-01 2021-03-31 0001497504 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001497504 us-gaap:CommonStockMember 2021-12-31 0001497504 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001497504 us-gaap:RetainedEarningsMember 2021-12-31 0001497504 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001497504 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001497504 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001497504 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001497504 us-gaap:CommonStockMember 2022-03-31 0001497504 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001497504 us-gaap:RetainedEarningsMember 2022-03-31 0001497504 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001497504 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001497504 us-gaap:CommonStockMember 2020-12-31 0001497504 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001497504 us-gaap:RetainedEarningsMember 2020-12-31 0001497504 2020-12-31 0001497504 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesBPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001497504 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001497504 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001497504 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001497504 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001497504 us-gaap:CommonStockMember 2021-03-31 0001497504 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001497504 us-gaap:RetainedEarningsMember 2021-03-31 0001497504 2021-03-31 0001497504 plxp:MediaAndAdvertisingCommitmentsMember 2022-03-31 0001497504 plxp:VAZALOREMember 2022-01-01 2022-03-31 0001497504 plxp:VAZALORE81MgDoseMember 2022-01-01 2022-03-31 0001497504 plxp:VAZALORE81MgDoseMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001497504 plxp:Vazalore325MgDoseMember 2022-01-01 2022-03-31 0001497504 plxp:Vazalore325MgDoseMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001497504 plxp:PublicOfferingMember 2021-03-05 2021-03-05 0001497504 plxp:PublicOfferingMember 2021-03-05 0001497504 us-gaap:OverAllotmentOptionMember 2021-03-05 0001497504 us-gaap:OverAllotmentOptionMember 2021-03-16 2021-03-16 0001497504 plxp:June2017WarrantsMember 2017-06-30 0001497504 plxp:June2017WarrantsMember 2017-08-09 0001497504 plxp:June2017WarrantsMember 2017-08-09 2017-08-09 0001497504 plxp:November2020WarrantsMember 2020-11-30 0001497504 plxp:June2017WarrantsMember 2021-12-31 0001497504 plxp:June2017WarrantsMember 2022-01-01 2022-03-31 0001497504 plxp:June2017WarrantsMember 2022-03-31 0001497504 plxp:November2020WarrantsMember 2021-12-31 0001497504 plxp:November2020WarrantsMember 2022-01-01 2022-03-31 0001497504 plxp:November2020WarrantsMember 2022-03-31 0001497504 plxp:SVBWarrantsMember 2021-12-31 0001497504 plxp:SVBWarrantsMember 2022-01-01 2022-03-31 0001497504 plxp:SVBWarrantsMember 2022-03-31 0001497504 2021-01-01 2021-12-31 0001497504 plxp:The2018IncentivePlanMember 2018-09-13 2018-09-13 0001497504 plxp:The2018IncentivePlanMember 2021-11-09 2021-11-09 0001497504 plxp:The2018IncentivePlanMember 2018-09-13 0001497504 plxp:The2018IncentivePlanMember 2022-01-01 2022-03-31 0001497504 srt:MinimumMember us-gaap:EmployeeStockOptionMember plxp:The2018IncentivePlanMember 2022-01-01 2022-03-31 0001497504 srt:MaximumMember us-gaap:EmployeeStockOptionMember plxp:The2018IncentivePlanMember 2022-01-01 2022-03-31 0001497504 plxp:EmployeesMember us-gaap:EmployeeStockOptionMember plxp:The2018IncentivePlanMember 2022-01-01 2022-03-31 0001497504 us-gaap:EmployeeStockOptionMember plxp:The2018IncentivePlanMember 2022-01-01 2022-03-31 0001497504 srt:MinimumMember 2022-03-31 0001497504 srt:MaximumMember 2022-03-31 0001497504 us-gaap:OtherCurrentLiabilitiesMember 2022-03-31 0001497504 us-gaap:OtherNoncurrentLiabilitiesMember 2022-03-31 0001497504 srt:ScenarioForecastMember plxp:MediaAndAdvertisingCommitmentsMember 2022-06-30 0001497504 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-03-31 0001497504 plxp:DerivativeWarrantLiabilityMember 2020-12-31 0001497504 plxp:DerivativeWarrantLiabilityMember 2021-01-01 2021-12-31 0001497504 plxp:DerivativeWarrantLiabilityMember 2021-12-31 0001497504 us-gaap:FairValueInputsLevel1Member plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel2Member plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel3Member plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001497504 us-gaap:FairValueInputsLevel1Member plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 us-gaap:FairValueInputsLevel2Member plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 us-gaap:FairValueInputsLevel3Member plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 plxp:DerivativeWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001497504 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y 0001497504 PLx Pharma Inc. false --12-31 Q1 2022

0.001

12642000000

45000

12642

0.001

2492722000

25000

2364

0.001

930000

0.001

100000000

27539229

1700000

3033047

9517191

20485741

P5Y

P7Y3M7D

10-Q true 2022-03-31 false 001-36351 DE 46-4995704 9 Fishers Lane, Suite E Sparta NJ 07871 973 409-6541 Common Stock, $0.001 par value PLXP NASDAQ Yes Yes Non-accelerated Filer true false false 27539229

52499000

69392000

698000

634000

3839000

2458000

712000

992000

57748000

73476000

828000

858000

204000

230000

2061000

17000

60858000

76642000

12716000

10600000

394000 1163000

120000

116000

13230000

11879000

5410000

12818000

129000 129000

106000

136000

18875000

24962000

13708000

2306000

28000

185000000

183912000

-159059000

-148274000

25969000

35666000

60858000

76642000

2083000

1169000

914000

654000

959000

18456000

2636000

19110000

3595000

-18196000

-3595000

3000

-10000

-7408000

7935000

7411000

-7945000

-10785000

-11540000

-10785000

-11540000

-0

322000

-10785000 -11862000

-0.39

-0.73

27539229

16361583

12642

13708000

27539229

28000

183912000

-148274000

35666000

1088000

-10785000

12642

13708000

2364

2306000

27539229

28000

185000000

-159059000

25969000

15000

13662000

8000

7723000

13911633

14000

91203000

-102149000

-10932000

573000

217000

105000

8924700 9000 66873000 66882000

-11540000

15000

13662000

8000

7723000

22836333

23000

158327000

-113689000

44661000

-10785000

-11540000

30000

27000

1088000

573000

-26000 -77000

3000

-7408000

7935000

-0

-28000

64000

-0

1381000

-0

-280000

-138000

2116000

100000

-769000 -938000 0 -597000

-26000

-88000

-16893000

-4282000

0 66882000

-0

625000

66257000

-16893000

61975000

69392000

22449000

52499000

84424000

602000

322000

NOTE 1. BACKGROUND AND ORGANIZATION Business Operations PLx Pharma Inc. (the “Company”, “we”, “our” or “us”), together with its subsidiary PLx Opco Inc., is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (“APIs”) are absorbed in the gastrointestinal ("GI") tract via its clinically-validated and patent-protected PLxGuard™ technology. The Company has two Food and Drug Administration (“FDA”) approved products, VAZALORE® 81 mg and VAZALORE® 325 mg (referred to together as “VAZALORE”), which are liquid-filled aspirin capsules for over-the-counter distribution ("OTC"). Impact of COVID-19 Pandemic on Financial Statements On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed and continue to enforce quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses. In response to COVID-19, the Company has not experienced a significant disruption or delay in the development, manufacturing or sale of VAZALORE, and has not otherwise experienced any significant negative impact on its financial condition, results of operations or cash flows. However, the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company has not experienced any significant negative impact on its March 31, 2022 unaudited consolidated financial statements related to COVID-19.

NOTE 2. LIQUIDITY The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations and potential other funding sources, in addition to cash on-hand, to meet its obligations as they become due. The Company had not generated any revenue from the sale of products prior to the quarter ended September 30, 2021 and has incurred operating losses in each year since it commenced operations. The Company began generating revenue in the U.S. from its sales of VAZALORE in the third quarter of 2021. The Company expects to continue to incur significant operating expenses and operating losses for the foreseeable future as the Company continues the commercialization of VAZALORE. Additionally, as of March 31, 2022, the Company had entered into media and advertising commitments for VAZALORE of $2.9 million which are expected to be paid in the second quarter of 2022. Further, the Company has supply agreements with its contract manufacturer and packager for VAZALORE which contain minimum annual purchase commitments that started in 2021 and continue through 2025; the minimum annual purchase commitments are intended to ensure that manufactured product is available when required to enable the Company to meet its expected market demand for VAZALORE. As of March 31, 2022, the Company had working capital of $44.5 million, including cash and cash equivalents of $52.5 million. Although the achievement of future profitable operations and the ability to generate sufficient cash from operations is uncertain at this time, the Company’s cash on hand at March 31, 2022 supports that the Company can fund its obligations for at least one year from the date these financial statements were issued and mitigates the substantial doubt consideration.

2900000

44500000

52500000

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Accounting and Principles of Consolidation The accompanying consolidated financial statements are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The December 31, 2021 consolidated balance sheet included herein was derived from audited consolidated financial statements as of that date. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously filed in its Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, the unaudited interim consolidated financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2022 and the results of operations for the three months ended March 31, 2022 and 2021. The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, PLx Opco Inc. All significant intercompany balances and transactions have been eliminated within the unaudited consolidated financial statements. Use of Estimates The preparation of our unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, the fair value of warrant liability, the fair value of stock-based compensation, trade promotional allowances, allowance for inventory obsolescence, and deferred taxes and associated valuation allowance. Actual results could differ from those estimates. Inventory Inventory is stated at the lower of cost or net realizable value, using the first-in first-out method based on actual costs. Inventory as of March 31, 2022 and December 31, 2021 was comprised of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Description </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="5" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; vertical-align: bottom;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Raw Materials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">132</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Work-in-Progress </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Finished Goods </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Inventory </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,839</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,458</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> The Company regularly reviews inventory quantities on hand and assesses the need for an allowance for obsolescence based on estimates of net realizable value. The allowance for obsolete inventory as of March 31, 2022 and December 31, 2021 was not material. Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 mg and 325 mg doses in the third quarter of 2021 and recognizes revenue, at a point in time, when control of a promised good is transferred to a customer in an amount that reflects consideration that the Company expects to be entitled to in exchange for that good. This occurs either when the finished goods are received by the customer or when a product is picked up by the customer or the customer’s carrier. The Company recognized total revenue from sales of VAZALORE of $2.1 million with $1.7 million or 79% of net sales for the 81 mg dose and $0.4 million or 21% of net sales for the 325 mg dose for the three months ended March 31, 2022. Nature of Goods and Services The Company generates revenue from the sale of its VAZALORE products through a broad distribution platform that includes drugstores, mass merchandisers, grocery stores, and e-commerce channels, all of which sell its products to consumers. Finished goods products are typically shipped FOB destination and accordingly, the Company recognizes revenue upon delivery to the customer or pick-up by the customer’s carrier. Satisfaction of Performance Obligations The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. The Company had no unsatisfied performance obligations or deferred revenue as of March 31, 2022. Variable Consideration Provisions for certain customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales, based on an estimate of future returns, and customer prompt payment discounts, redemption of coupons by consumers and trade promotional allowances paid to customers. These allowances cover extensive promotional activities, primarily comprised of cooperative advertising, slotting, coupons, periodic price reduction arrangements, and other in-store displays. The reserves for sales returns and consumer and trade promotion obligations are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses trend experience and coupon redemption inputs to determine coupon reserve requirements and uses forecasted customer and sales organization inputs, and historical trend analysis for consumer brands to determine the reserves for other promotional activities and sales returns. The balance of reserves for sales returns and consumer and trade promotion obligations, reflected in the accompanying unaudited consolidated balance sheets in accounts payable and accrued liabilities, was $1.0 million as of March 31, 2022 and $1.3 million as of December 31, 2021. Advertising Advertising costs are expensed as they are incurred. The Company incurred advertising costs of $9.6 million during the three months ended March 31, 2022, which are included in SM&A expense in the unaudited consolidated statements of operations, and did not have any advertising costs during the three months ended March 31, 2021. Income (Loss) Per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series A convertible preferred stock (the “Series A Preferred Stock”) and the Series B convertible preferred stock (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, collectively the “Preferred Stock”) contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the Preferred Stock and excludes the impact of those shares from the denominator. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the Preferred Stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock using the if-converted method. Due to net losses, none of the participating securities nor potential dilutive securities had a dilutive impact during the three months ended March 31, 2022 and 2021. The following table sets forth the potential dilutive securities: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Stock Options </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,189,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,033,047</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,935,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Convertible Preferred Stock </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6,476,275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">9,517,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Potential Dilutive Shares </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,261,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,485,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> Recent Accounting Developments In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is designed to provide financial statement users with more information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. When determining such expected credit losses, the guidance requires companies to apply a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will evaluate the impact on the consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (subtopic 815-40) that provides new guidance on the accounting for convertible debt instruments and contracts in an entity’s own equity. The guidance simplifies the accounting for convertible instruments by reducing the various accounting models that can require the instrument to be separated into a debt component and equity component or derivative component. Additionally, the guidance eliminated certain settlement conditions previously required to be able to classify a derivative in equity. The new guidance is effective on a modified or full retrospective basis for fiscal years beginning after December 15, 2023, including interim periods with those fiscal years. The Company will evaluate the impact on the consolidated financial statements. The Company does not believe that any recently issued effective standards, or standards issued but not yet effective, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements. Subsequent Events The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration.

Basis of Accounting and Principles of Consolidation The accompanying consolidated financial statements are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The December 31, 2021 consolidated balance sheet included herein was derived from audited consolidated financial statements as of that date. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously filed in its Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, the unaudited interim consolidated financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2022 and the results of operations for the three months ended March 31, 2022 and 2021. The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, PLx Opco Inc. All significant intercompany balances and transactions have been eliminated within the unaudited consolidated financial statements.

Use of Estimates The preparation of our unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, the fair value of warrant liability, the fair value of stock-based compensation, trade promotional allowances, allowance for inventory obsolescence, and deferred taxes and associated valuation allowance. Actual results could differ from those estimates.

Inventory Inventory is stated at the lower of cost or net realizable value, using the first-in first-out method based on actual costs. Inventory as of March 31, 2022 and December 31, 2021 was comprised of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Description </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="5" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; vertical-align: bottom;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Raw Materials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">132</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Work-in-Progress </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Finished Goods </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Inventory </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,839</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,458</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> The Company regularly reviews inventory quantities on hand and assesses the need for an allowance for obsolescence based on estimates of net realizable value. The allowance for obsolete inventory as of March 31, 2022 and December 31, 2021 was not material.

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Description </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="5" rowspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; vertical-align: bottom;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Raw Materials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">132</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Work-in-Progress </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">338</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Finished Goods </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Inventory </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,839</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,458</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

164000

132000

1000

338000

3674000

1988000

3839000

2458000

Revenue Recognition The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. The Company began generating revenue in the U.S. from its sales of VAZALORE in 81 mg and 325 mg doses in the third quarter of 2021 and recognizes revenue, at a point in time, when control of a promised good is transferred to a customer in an amount that reflects consideration that the Company expects to be entitled to in exchange for that good. This occurs either when the finished goods are received by the customer or when a product is picked up by the customer or the customer’s carrier. The Company recognized total revenue from sales of VAZALORE of $2.1 million with $1.7 million or 79% of net sales for the 81 mg dose and $0.4 million or 21% of net sales for the 325 mg dose for the three months ended March 31, 2022. Nature of Goods and Services The Company generates revenue from the sale of its VAZALORE products through a broad distribution platform that includes drugstores, mass merchandisers, grocery stores, and e-commerce channels, all of which sell its products to consumers. Finished goods products are typically shipped FOB destination and accordingly, the Company recognizes revenue upon delivery to the customer or pick-up by the customer’s carrier. Satisfaction of Performance Obligations The Company recognizes revenue upon the satisfaction of its performance obligations (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. The Company had no unsatisfied performance obligations or deferred revenue as of March 31, 2022. Variable Consideration Provisions for certain customer promotional programs, product returns and discounts to customers are accounted for as variable consideration and recorded as a reduction in sales, based on an estimate of future returns, and customer prompt payment discounts, redemption of coupons by consumers and trade promotional allowances paid to customers. These allowances cover extensive promotional activities, primarily comprised of cooperative advertising, slotting, coupons, periodic price reduction arrangements, and other in-store displays. The reserves for sales returns and consumer and trade promotion obligations are established based on the Company’s best estimate of the amounts necessary to settle future and existing obligations for products sold as of the balance sheet date. The Company uses trend experience and coupon redemption inputs to determine coupon reserve requirements and uses forecasted customer and sales organization inputs, and historical trend analysis for consumer brands to determine the reserves for other promotional activities and sales returns. The balance of reserves for sales returns and consumer and trade promotion obligations, reflected in the accompanying unaudited consolidated balance sheets in accounts payable and accrued liabilities, was $1.0 million as of March 31, 2022 and $1.3 million as of December 31, 2021.

2100000

0.79

400000

0.21

1000000.0 1300000

Advertising Advertising costs are expensed as they are incurred. The Company incurred advertising costs of $9.6 million during the three months ended March 31, 2022, which are included in SM&A expense in the unaudited consolidated statements of operations, and did not have any advertising costs during the three months ended March 31, 2021.

9600000

Income (Loss) Per Share In periods of net loss, basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. The Company’s Series A convertible preferred stock (the “Series A Preferred Stock”) and the Series B convertible preferred stock (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, collectively the “Preferred Stock”) contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic earnings per share excludes from the numerator net income attributable to the Preferred Stock and excludes the impact of those shares from the denominator. In periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For periods of net income, diluted earnings per share is computed using the more dilutive of the “two class method” or the “treasury method.” Dilutive earnings per share under the “two class method” is calculated by dividing net income available to common stockholders as adjusted for the participating impacts of the Preferred Stock, by the weighted-average number of shares outstanding plus the dilutive impact of all other potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method. Dilutive earnings per share under the “treasury method” is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock using the if-converted method. Due to net losses, none of the participating securities nor potential dilutive securities had a dilutive impact during the three months ended March 31, 2022 and 2021. The following table sets forth the potential dilutive securities: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Stock Options </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,189,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,033,047</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,935,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Convertible Preferred Stock </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6,476,275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">9,517,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Potential Dilutive Shares </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,261,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,485,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Stock Options </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,189,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,033,047</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,935,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Convertible Preferred Stock </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6,476,275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">9,517,191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Potential Dilutive Shares </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,261,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,485,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

4189006

6596096

7935503

6476275

17261377

Recent Accounting Developments In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which is designed to provide financial statement users with more information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. When determining such expected credit losses, the guidance requires companies to apply a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will evaluate the impact on the consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (subtopic 815-40) that provides new guidance on the accounting for convertible debt instruments and contracts in an entity’s own equity. The guidance simplifies the accounting for convertible instruments by reducing the various accounting models that can require the instrument to be separated into a debt component and equity component or derivative component. Additionally, the guidance eliminated certain settlement conditions previously required to be able to classify a derivative in equity. The new guidance is effective on a modified or full retrospective basis for fiscal years beginning after December 15, 2023, including interim periods with those fiscal years. The Company will evaluate the impact on the consolidated financial statements. The Company does not believe that any recently issued effective standards, or standards issued but not yet effective, if adopted, would have a material effect on the accompanying unaudited consolidated financial statements.

Subsequent Events The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration.

NOTE 4. STOCKHOLDERS’ EQUITY Common Stock On March 5, 2021, the Company completed an underwritten public offering in which the Company issued and sold 7,875,000 shares of the Company’s common stock at a price to the public of $8.00 per share (the "Offering"). Gross proceeds of the Offering were $63 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company and resulted in net proceeds of $59.0 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The underwriters retained a customary 30-day overallotment option to purchase up to 1,181,250 shares of common stock at the public offering price, less underwriting discounts and commission. The overallotment option was exercised on March 16, 2021 for 1,049,700 shares with gross proceeds of $8.4 million and net proceeds of $7.9 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company. Warrants In June 2017, the Company issued stock purchase warrants to purchase 2,646,091 shares of common stock at an exercise price of $7.50 per share. The warrants, exercisable beginning six months and one day after issuance, have a 10-year term and are liability classified due to the holders’ right to require the Company to repurchase the warrants for cash upon certain deferred fundamental transactions ( “June 2017 Warrants”). See Note 7 for the fair value measurement of the warrant liability. In connection with the entry into the Term Loan Facility, the Company issued to SVB and one of its affiliates stock purchase warrants to purchase an aggregate of 58,502 shares of the Company’s common stock at an exercise price of $6.41 per share. These warrants are immediately exercisable, have a 10-year term, contain a cashless exercise provision, and are classified in equity. In November 2020, the Company issued warrants to purchase 5,230,910 shares of common stock which have an exercise price of $4.31 per share, contain a cashless exercise provision, will expire five years from the date of issuance and are equity classified (the “November 2020 Warrants”). The following is a summary of warrant activity for the three months ended March 31, 2022: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> Description </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding 12/31/2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercised </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding 3/31/22 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercise Price </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Remaining Contractual Term (in years) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> June 2017 Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,457,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,457,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> November 2020 Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,109,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,109,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> SVB Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">29,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">29,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6.41</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">5.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">4.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">4.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> Stock Options The following is a summary of stock option activity for the three months ended March 31, 2022: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"> <tbody> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Term (in years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value (in thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Outstanding, December 31, 2021 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,498,297</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.27</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,456</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">760,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised, cancelled, or forfeited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(69,291</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> ) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14.44</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding, March 31, 2022 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,189,006</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.08</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.64</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable, March 31, 2022 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,116,338</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">629</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table> On September 13, 2018, the Company’s stockholders approved the 2018 Incentive Plan (as amended from time to time, the “2018 Plan”). The 2018 Plan provides that the Company may grant equity interests to employees, consultants, and members of the Board of Directors in the form of incentive and nonqualified stock options, restricted stock and restricted stock units, stock appreciation rights and various other forms of stock-based awards. On November 10, 2020, the Company held its 2020 annual meeting of stockholders at which the Company’s stockholders approved an amendment to the 2018 Plan, to increase the number of shares of the Company’s common stock issuable under the 2018 Plan by 1,750,000 shares. On November 9, 2021, the Company held its 2021 annual meeting of stockholders at which the Company’s stockholders approved an amendment to the 2018 Plan to increase the number of shares of the Company’s common stock issuable under the 2018 Plan by 4,000,000 shares (the “Plan Amendment”). The Board of Directors of the Company previously approved the Plan Amendment on August 3, 2021, subject to stockholder approval. There are 7,000,000 shares authorized for issuance pursuant to the 2018 Plan, of which 3,669,650 shares are available for issuance under the 2018 Plan. Prior to the approval of the 2018 Plan, the Company granted options to employees, directors, advisors, and consultants from two former plans – the Old PLx Omnibus Stock Option Plan and the Dipexium 2013 Equity Incentive Plan (the “Prior Plans”). Upon the adoption of the 2018 Plan, the Prior Plans were frozen, and no new awards can be issued pursuant to the Prior Plans. The Company is no longer authorized to grant awards under these two plans. The Company granted 760,000 options during the three months ended March 31, 2022 with an aggregate fair value of $2.7 million calculated using the Black-Scholes model on the grant date. Variables used in the Black-Scholes model include: (1) discount rate ranging from 1.6% - 1.9%, (2) expected life of 6 years, (3) expected volatility of 82%, and (4) zero expected dividends. As of March 31, 2022, the Company had $9.0 million in unamortized expense related to unvested options which is expected to be expensed over a weighted average of 2.2 years. During the three months ended March 31, 2022 and 2021, the Company recorded $1.1 million and $0.6 million, respectively, in total stock-based compensation expense related to the stock options. Substantially all stock-based compensation expense is classified as selling, marketing and administrative expenses in the accompanying unaudited consolidated statements of operations.

7875000

8.00

63000000

59000000.0 1181250

1049700

8400000

7900000

2646091

7.50

P10Y

58502

6.41

P10Y

5230910

4.31

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> Description </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding 12/31/2021 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercised </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding 3/31/22 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercise Price </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Remaining Contractual Term (in years) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> June 2017 Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,457,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,457,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> November 2020 Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,109,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,109,344</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> SVB Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">29,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">29,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6.41</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">5.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> Total Warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">6,596,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">4.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">4.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

2457501

-0

2457501

7.50

P5Y2M12D 0

4109344

-0

4109344

4.31

P3Y7M6D 0

29251

-0

29251

6.41

P5Y4M24D 0

6596096

-0

6596096

4.47

P4Y2M12D 0

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"> <tbody> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Term (in years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Value (in thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Outstanding, December 31, 2021 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,498,297</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.27</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,456</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">760,000</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.07</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised, cancelled, or forfeited </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(69,291</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> ) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14.44</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding, March 31, 2022 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,189,006</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.08</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7.64</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">946</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable, March 31, 2022 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,116,338</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10.75</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.1</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">629</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table>

3498297

10.07

7456000

760000

5.07

69291

14.44

4189006

9.08

P7Y7M20D

946000

2116338

10.75

P6Y1M6D

629000

1750000

4000000

7000000

3669650

760000

2700000 0.016 0.019

P6Y

0.82

9000000.0

P2Y2M12D

1100000

600000

NOTE 5. COMMITMENTS AND CONTINGENCIES Lease Agreements The Company presently leases office space under operating lease agreements, expiring in September 2023, and June 2024. The office leases require the Company to pay for its maintenance, and insurance. Rental expense under these agreements was $0.03 million and $0.09 million for the three months ended March 31, 2022 and 2021, respectively. Operating lease ROU assets are included in right of use assets in the Company's unaudited consolidated balance sheets. Operating lease liabilities are included in other current and non-current liabilities in the Company’s unaudited consolidated balance sheets. All the Company’s existing leases as of March 31, 2022 are classified as operating leases and have a weighted average remaining lease term of 1.9 years. Certain of the Company’s existing leases have fair value renewal options, none of which the Company considers certain of being exercised or included in the minimum lease term. The discount rate used in the calculation of the Company’s lease liability ranges from 7.25% to 9.50%. A maturity analysis of the Company’s operating leases follows: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Future undiscounted cash flows: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">98,756</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">113,823</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30,132</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">242,711</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Discount factor </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,851</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Lease liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">222,860</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current lease liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(117,131</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-current lease liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">105,729</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> Purchase Commitments As of March 31, 2022, the Company had entered into media and advertising commitments for VAZALORE of $2.9 million which are expected to be paid during the second quarter of 2022. The Company has supply agreements with its contract manufacturer and packager for VAZALORE which contain minimum annual purchase commitments that started in 2021 and continue through 2025. The minimum annual purchase commitments are intended to ensure that manufactured product is available when required to enable the Company to meet its expected market demand for VAZALORE.

30000.00

90000.00

P1Y10M24D

0.0725

0.0950

98756000

113823000

30132000

242711000

19851000

222860000

117131000

105729000

2900000

NOTE 6. FAIR VALUE MEASUREMENTS Fair value is defined as the price that would be received in the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company has categorized all investments recorded at fair value based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> ● </td><td style="vertical-align:top;width:auto;"> Level 1: Quoted prices in active markets for identical assets or liabilities that the organization has the ability to access at the reporting date. </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> ● </td><td style="vertical-align:top;width:auto;"> Level 2: Inputs other than quoted prices included in Level 1, which are either observable or that can be derived from or corroborated by observable data as of the reporting date. </td></tr> <tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:3.3%;"> ● </td><td style="vertical-align:top;width:auto;"> Level 3: Inputs include those that are significant to the fair value of the asset or liability and are generally less observable from objective resources and reflect the reporting entity’s subjective determinations regarding the assumptions market participants would use in pricing the asset or liability. </td></tr> </tbody></table> The Company’s financial instruments (cash and cash equivalents, receivables, and accounts payable) are carried in the consolidated balance sheet at cost, which reasonably approximates fair value based on their short-term nature. The Company’s warrant liability is recorded at fair value, with changes in fair value being reflected in the statements of operations for the period of change. Financial assets and liabilities measured at fair value on a recurring basis The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy. The June 2017 Warrants contain certain cash settlement features and, accordingly, the Company considered them to be liabilities and accounted for them at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a binomial asset pricing model that consisted of a conditional probability weighted expected return method that values the Company’s equity securities assuming various possible future outcomes to estimate the allocation of value within one or more of the scenarios. Using this method, unobservable inputs included the Company’s equity value, expected timing of possible outcomes, risk free interest rates and stock price volatility. Variables used at March 31, 2022 include: (1) the Company stock price of $4.04, (2) the risk-free rate of 2.42%, (3) remaining expected life of 5.2 years, and (4) expected volatility of 82%. The Series A Preferred Stock and the Series B Preferred Stock both contain a contingent put option and, accordingly, the Company considered the put options to be liabilities and accounted for them at fair value using Level 3 inputs. The Company determined the fair value of these liabilities was de minimis at issuance and as of March 31, 2022, due to the remote possibly of its occurrence, a Level 3 unobservable input. The following table sets forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the three months ended March 31, 2022: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Balance at December 31, 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Established in 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Change in Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Balance at March 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7,408</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> ) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> The following table identifies the carrying amounts of such liabilities at March 31, 2022 and December 31, 2021: <table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at March 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2021 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> Financial assets and liabilities carried at fair value on a non-recurring basis The Company does not have any financial assets or liabilities measured at fair value on a non-recurring basis. Non-financial assets and liabilities carried at fair value on a recurring basis The Company does not have any non-financial assets or liabilities measured at fair value on a recurring basis. Non-financial assets and liabilities carried at fair value on a non-recurring basis The Company measures its long-lived assets, including property and equipment and goodwill, at fair value on a non-recurring basis when they are deemed to be impaired. No such impairment was recognized during the three months ended March 31, 2022 and 2021.

4.04

2.42

5.2

12818000

-0

7408000

5410000

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at March 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 98%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrant liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2021 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,818</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

5410000

12818000

NOTE 7. SUBSEQUENT EVENTS The Company’s management reviewed all material events through the date the unaudited consolidated financial statements were issued for subsequent event disclosure consideration and none were noted.

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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� -24 !@ ("!'3 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ S3NM M5/2ST$>X#0 -2H !D ("!*D\ 'AL+W=O&PO=V]R:W-H965TJ#L0, % ( 9 " @8!@ !X;"]W;W)K M&UL4$L! A0#% @ S3NM5/62+9Z4 @ 8 4 M !D ("!:&0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ S3NM5/,?<9*3 P 7PP !D M ("!NFP 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ S3NM5//C6F+X!@ LB( !D ("!!78 'AL+W=O M&PO=V]R:W-H965T! M !X;"]W;W)K&UL4$L! A0#% @ S3NM5/1( M5'$: P V D !D ("!R84 'AL+W=O&PO=V]R:W-H965T^0( (L) 9 " @0., !X;"]W;W)K&UL4$L! A0#% @ S3NM5'JDJXER @ K 4 !D M ("!,X\ 'AL+W=O&PO M=V]R:W-H965T K !;0V]N=&5N=%]4>7!E&UL4$L%!@ F "8 00H ,^? $! end XML 43 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 103 201 1 false 38 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://plxpharma.com/20220331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited- Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited- Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Unaudited) Sheet http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flow (Unaudited) Sheet http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited- Consolidated Statements of Cash Flow (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Background and Organization Sheet http://plxpharma.com/20220331/role/statement-note-1-background-and-organization Note 1 - Background and Organization Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Liquidity Sheet http://plxpharma.com/20220331/role/statement-note-2-liquidity Note 2 - Liquidity Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies Note 3 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Stockholders' Equity Sheet http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity Note 4 - Stockholders' Equity Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Commitments and Contingencies Sheet http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies Note 5 - Commitments and Contingencies Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Fair Value Measurements Sheet http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements Note 6 - Fair Value Measurements Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Subsequent Events Sheet http://plxpharma.com/20220331/role/statement-note-7-subsequent-events Note 7 - Subsequent Events Notes 13 false false R14.htm 013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies 14 false false R15.htm 014 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Tables http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies 15 false false R16.htm 015 - Disclosure - Note 4 - Stockholders' Equity (Tables) Sheet http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables Note 4 - Stockholders' Equity (Tables) Tables http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity 16 false false R17.htm 016 - Disclosure - Note 5 - Commitments and Contingencies (Tables) Sheet http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables Note 5 - Commitments and Contingencies (Tables) Tables http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies 17 false false R18.htm 017 - Disclosure - Note 6 - Fair Value Measurements (Tables) Sheet http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables Note 6 - Fair Value Measurements (Tables) Tables http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements 18 false false R19.htm 018 - Disclosure - Note 2 - Liquidity (Details Textual) Sheet http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual Note 2 - Liquidity (Details Textual) Details http://plxpharma.com/20220331/role/statement-note-2-liquidity 19 false false R20.htm 019 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Details http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables 20 false false R21.htm 020 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Inventory (Details) Sheet http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details Note 3 - Summary of Significant Accounting Policies - Inventory (Details) Details http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables 21 false false R22.htm 021 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) Sheet http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) Details 22 false false R23.htm 022 - Disclosure - Note 4 - Stockholders' Equity (Details Textual) Sheet http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual Note 4 - Stockholders' Equity (Details Textual) Details http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables 23 false false R24.htm 023 - Disclosure - Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details) Sheet http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details) Details 24 false false R25.htm 024 - Disclosure - Note 4 - Stockholders' Equity - Stock Option Activity (Details) Sheet http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details Note 4 - Stockholders' Equity - Stock Option Activity (Details) Details 25 false false R26.htm 025 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual) Sheet http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual Note 5 - Commitments and Contingencies (Details Textual) Details http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables 26 false false R27.htm 026 - Disclosure - Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details) Sheet http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details) Details 27 false false R28.htm 027 - Disclosure - Note 6 - Fair Value Measurements (Details Textual) Sheet http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual Note 6 - Fair Value Measurements (Details Textual) Details http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables 28 false false R29.htm 028 - Disclosure - Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details) Sheet http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details) Details 29 false false R30.htm 029 - Disclosure - Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details) Sheet http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details) Details 30 false false All Reports Book All Reports plxp20220331_10q.htm ex_364549.htm ex_364550.htm ex_364551.htm plxp-20220331.xsd plxp-20220331_cal.xml plxp-20220331_def.xml plxp-20220331_lab.xml plxp-20220331_pre.xml picture1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 48 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "plxp20220331_10q.htm": { "axisCustom": 0, "axisStandard": 18, "contextCount": 103, "dts": { "calculationLink": { "local": [ "plxp-20220331_cal.xml" ] }, "definitionLink": { "local": [ "plxp-20220331_def.xml" ] }, "inline": { "local": [ "plxp20220331_10q.htm" ] }, "labelLink": { "local": [ "plxp-20220331_lab.xml" ] }, "presentationLink": { "local": [ "plxp-20220331_pre.xml" ] }, "schema": { "local": [ "plxp-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 316, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 46, "http://xbrl.sec.gov/dei/2022": 6, "total": 52 }, "keyCustom": 20, "keyStandard": 181, "memberCustom": 13, "memberStandard": 24, "nsprefix": "plxp", "nsuri": "http://plxpharma.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://plxpharma.com/20220331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Stockholders' Equity", "role": "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "shortName": "Note 4 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Commitments and Contingencies", "role": "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "shortName": "Note 5 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Fair Value Measurements", "role": "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "shortName": "Note 6 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Subsequent Events", "role": "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events", "shortName": "Note 7 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)", "role": "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 4 - Stockholders' Equity (Tables)", "role": "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables", "shortName": "Note 4 - Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 5 - Commitments and Contingencies (Tables)", "role": "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables", "shortName": "Note 5 - Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 6 - Fair Value Measurements (Tables)", "role": "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables", "shortName": "Note 6 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "plxp:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 2 - Liquidity (Details Textual)", "role": "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "shortName": "Note 2 - Liquidity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "plxp:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-6", "lang": null, "name": "plxp:ReservesForSalesReturnsAndConsumerAndTradePromotionObligations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Inventory (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details", "shortName": "Note 3 - Summary of Significant Accounting Policies - Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "plxp:IncrementalWeightedAverageSharesAttributableToDilutiveEffectTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details", "shortName": "Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "plxp:IncrementalWeightedAverageSharesAttributableToDilutiveEffectTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 4 - Stockholders' Equity (Details Textual)", "role": "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "shortName": "Note 4 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-6", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details", "shortName": "Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Stockholders' Equity - Stock Option Activity (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details", "shortName": "Note 4 - Stockholders' Equity - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)", "role": "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual", "shortName": "Note 5 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details", "shortName": "Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 6 - Fair Value Measurements (Details Textual)", "role": "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual", "shortName": "Note 6 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2020-12-31_FairValueByLiabilityClassAxis-DerivativeWarrantLiabilityMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details", "shortName": "Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2020-12-31_FairValueByLiabilityClassAxis-DerivativeWarrantLiabilityMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details)", "role": "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "shortName": "Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2022-03-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2020-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Unaudited)", "role": "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited", "shortName": "Consolidated Statements of Changes in Series A And Series B Convertible Preferred Stock and Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "i_2020-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flow (Unaudited)", "role": "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "shortName": "Consolidated Statements of Cash Flow (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-4", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Background and Organization", "role": "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization", "shortName": "Note 1 - Background and Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Liquidity", "role": "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "shortName": "Note 2 - Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "role": "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "shortName": "Note 3 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "plxp20220331_10q.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-document-and-entity-information", "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization", "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables", "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events", "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-document-and-entity-information", "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization", "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables", "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events", "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "plxp_AccruedBonusesAndSeverancesCurrent": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements and for severances. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued bonuses" } } }, "localname": "AccruedBonusesAndSeverancesCurrent", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_ClassOfWarrantOrRightAggregateIntrinsicValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate intrinsic value related to class of warrant or right.", "label": "Aggregate Intrinsic Value" } } }, "localname": "ClassOfWarrantOrRightAggregateIntrinsicValue", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "monetaryItemType" }, "plxp_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during period.", "label": "plxp_ClassOfWarrantOrRightExercisedDuringPeriod", "negatedLabel": "Warrants exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "sharesItemType" }, "plxp_ClassOfWarrantOrRightRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents class of warrant or right, remaining contractual term.", "label": "Remaining Contractual Term (Year)" } } }, "localname": "ClassOfWarrantOrRightRemainingContractualTerm", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "durationItemType" }, "plxp_ClassOfWarrantOrRightTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exercisable period of time after issuance for warrants and rights, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "plxp_ClassOfWarrantOrRightTerm", "terseLabel": "Class of Warrant or Right, Term (Year)" } } }, "localname": "ClassOfWarrantOrRightTerm", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "plxp_DerivativeWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the derivative warrant liability.", "label": "Derivative Warrant Liability [Member]" } } }, "localname": "DerivativeWarrantLiabilityMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "plxp_DividendsPayableNoncurrent": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding, classified as noncurrent.", "label": "Accrued dividends" } } }, "localname": "DividendsPayableNoncurrent", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the employees of the company.", "label": "Employees [Member]" } } }, "localname": "EmployeesMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "plxp_FinancingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents financing, shares.", "label": "Financing (in shares)" } } }, "localname": "FinancingShares", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "plxp_FinancingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents financing, value.", "label": "Financing" } } }, "localname": "FinancingValue", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "plxp_IncreaseDecreaseInBonusesAndSeverances": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in bonuses and severances.", "label": "plxp_IncreaseDecreaseInBonusesAndSeverances", "terseLabel": "Accrued bonuses" } } }, "localname": "IncreaseDecreaseInBonusesAndSeverances", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_IncreaseDecreaseInInterestPayableNetExcludingRelatedParties": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties excluding related parties for interest earned on loans or credit extended to the reporting entity.", "label": "plxp_IncreaseDecreaseInInterestPayableNetExcludingRelatedParties", "terseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNetExcludingRelatedParties", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of operating lease right of use assets.", "label": "plxp_IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "negatedLabel": "Amortization of right of use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_IncrementalWeightedAverageSharesAttributableToDilutiveEffectTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of incremental weighted average shares attributable to dilutive effect", "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Table Text Block]" } } }, "localname": "IncrementalWeightedAverageSharesAttributableToDilutiveEffectTableTextBlock", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "plxp_June2017WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the warrants issued on June 14, 2017.", "label": "June 2017 Warrants [Member]" } } }, "localname": "June2017WarrantsMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "domainItemType" }, "plxp_MediaAndAdvertisingCommitmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rerpesents the media and advertising commitments.", "label": "Media and Advertising Commitments [Member]" } } }, "localname": "MediaAndAdvertisingCommitmentsMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "plxp_NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, but before the impact of participation rights; of income (loss) available to common shareholders", "label": "plxp_NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights", "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_November2020WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents November 2020 warrants.", "label": "November 2020 Warrants [Member]" } } }, "localname": "November2020WarrantsMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "domainItemType" }, "plxp_ProceedsFromIssuanceOfCommonStockNetIssuanceCosts": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity, less the issuance costs including legal and commission fees.", "label": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetIssuanceCosts", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "plxp_ProceedsFromIssuanceOfCommonStockNetOfDiscountsAndIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock net of discounts and stock issuance costs.", "label": "plxp_ProceedsFromIssuanceOfCommonStockNetOfDiscountsAndIssuanceCosts", "terseLabel": "Proceeds from Issuance of Common Stock, Net of Discounts and Issuance Costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfDiscountsAndIssuanceCosts", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "plxp_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The concurrent sale of stock by a private company to the public.", "label": "Public Offering [Member]" } } }, "localname": "PublicOfferingMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "plxp_ReservesForSalesReturnsAndConsumerAndTradePromotionObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount of reserves for sales returns and consumer and trade promotion obligations.", "label": "plxp_ReservesForSalesReturnsAndConsumerAndTradePromotionObligations", "terseLabel": "Reserves for Sales Returns and Consumer and Trade Promotion Obligations" } } }, "localname": "ReservesForSalesReturnsAndConsumerAndTradePromotionObligations", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "plxp_SVBWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to SVB warrants.", "label": "SVB Warrants [Member]" } } }, "localname": "SVBWarrantsMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "domainItemType" }, "plxp_SaleOfStockOptionToPurchaseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares with an option to purchase under the sale of stock.", "label": "plxp_SaleOfStockOptionToPurchaseShares", "terseLabel": "Sale of Stock, Option to Purchase Shares (in shares)" } } }, "localname": "SaleOfStockOptionToPurchaseShares", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "plxp_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Series A Convertible Preferred Stock.", "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "domainItemType" }, "plxp_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Series B Convertible Preferred Stock.", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "domainItemType" }, "plxp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The discount rate assumption that is used in valuing an option on it own shares.", "label": "plxp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "plxp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "plxp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "plxp_The2018IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2018 incentive plan.", "label": "The 2018 Incentive Plan [Member]" } } }, "localname": "The2018IncentivePlanMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "plxp_VAZALORE81MgDoseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to VAZALORE 81 mg Dose.", "label": "VAZALORE 81 mg Dose [Member]" } } }, "localname": "VAZALORE81MgDoseMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "plxp_VAZALOREMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Vazalore.", "label": "VAZALORE [Member]" } } }, "localname": "VAZALOREMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "plxp_Vazalore325MgDoseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to VAZALORE 81 mg Dose.", "label": "VAZALORE 325 mg Dose [Member]" } } }, "localname": "Vazalore325MgDoseMember", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "plxp_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.", "label": "plxp_WorkingCapital", "terseLabel": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://plxpharma.com/20220331", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "plxp_statement-statement-note-3-summary-of-significant-accounting-policies-inventory-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies - Inventory (Details)" } } }, "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-inventory-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)" } } }, "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-3-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-4-stockholders-equity-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Stockholders' Equity - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-4-stockholders-equity-stock-option-activity-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-4-stockholders-equity-summary-of-warrant-activities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Stockholders' Equity - Summary of Warrant Activities (Details)" } } }, "localname": "statement-statement-note-4-stockholders-equity-summary-of-warrant-activities-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-4-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Stockholders' Equity" } } }, "localname": "statement-statement-note-4-stockholders-equity-tables", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Commitments and Contingencies - Maturity of Operating Leases (Details)" } } }, "localname": "statement-statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-5-commitments-and-contingencies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Commitments and Contingencies" } } }, "localname": "statement-statement-note-5-commitments-and-contingencies-tables", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value Measurements - Carrying Amount of Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value Measurements - Measured at Fair Value on a Recurring Basis (Details)" } } }, "localname": "statement-statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-note-6-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value Measurements" } } }, "localname": "statement-statement-note-6-fair-value-measurements-tables", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "plxp_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://plxpharma.com/20220331", "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r160", "r161", "r162", "r163", "r176", "r187", "r225", "r227", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r358", "r360", "r369", "r370" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r160", "r161", "r162", "r163", "r176", "r187", "r225", "r227", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r358", "r360", "r369", "r370" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r136", "r161", "r162", "r213", "r214", "r336", "r357", "r359" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r136", "r161", "r162", "r213", "r214", "r336", "r357", "r359" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r155", "r160", "r161", "r162", "r163", "r176", "r187", "r216", "r225", "r227", "r256", "r257", "r258", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r358", "r360", "r369", "r370" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r155", "r160", "r161", "r162", "r163", "r176", "r187", "r216", "r225", "r227", "r256", "r257", "r258", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r358", "r360", "r369", "r370" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r81", "r226" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r81", "r86", "r159", "r226" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r81", "r86", "r159", "r226", "r322" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r139", "r317" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r140", "r141" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r73", "r74", "r75", "r263", "r264", "r265", "r283" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "auth_ref": [ "r199", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "negatedLabel": "Preferred stock - declared dividends" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r228", "r266", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r60", "r178", "r181", "r182", "r308" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of debt discounts and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r60", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r70", "r125", "r128", "r134", "r143", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r276", "r278", "r300", "r318", "r320", "r339", "r348" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r30", "r70", "r143", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r276", "r278", "r300", "r318", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT ASSETS" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r72", "r120" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r10", "r62" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r56", "r62", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "terseLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r56", "r62", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r56", "r301" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r14", "r15", "r16", "r68", "r70", "r88", "r93", "r96", "r98", "r100", "r107", "r108", "r109", "r143", "r165", "r169", "r170", "r171", "r174", "r175", "r185", "r186", "r189", "r193", "r199", "r300", "r377" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r202", "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r341", "r352" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r164", "r368" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r73", "r74", "r283" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $0.001 par value; 100,000,000 shares authorized; 27,539,229 shares issued and outstanding at March 31, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r115", "r116", "r138", "r298", "r299", "r367" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r115", "r116", "r138", "r298", "r299", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r115", "r116", "r138", "r298", "r299", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r115", "r116", "r138", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r115", "r116", "r138", "r298", "r299", "r367" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r50", "r70", "r143", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r300" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Costs of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Inventory, net" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "us-gaap_DepositsAssetsNoncurrent", "terseLabel": "Security deposit" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r60", "r123" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r38", "r39", "r40", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "us-gaap_DerivativeLiabilities", "terseLabel": "Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Warrant liability" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization", "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r201", "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Preferred stock dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r78", "r79", "r80", "r81", "r82", "r87", "r88", "r98", "r99", "r100", "r103", "r104", "r284", "r285", "r344", "r354" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share, basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r73", "r74", "r75", "r77", "r83", "r85", "r106", "r144", "r199", "r201", "r263", "r264", "r265", "r272", "r273", "r283", "r302", "r303", "r304", "r305", "r306", "r307", "r316", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r60", "r183" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Change in fair value of warrant liability", "negatedLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r177", "r179", "r180", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r287", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r286", "r287", "r289", "r290", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r177", "r217", "r218", "r223", "r224", "r287", "r324" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r177", "r179", "r180", "r217", "r218", "r223", "r224", "r287", "r325" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r177", "r179", "r180", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r287", "r326" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r291", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedTerseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "negatedTerseLabel": "Established" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r177", "r179", "r180", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Loss on sale of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r11", "r149", "r150", "r151", "r152", "r320", "r338" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r49", "r70", "r125", "r127", "r130", "r133", "r135", "r143", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r300" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r46", "r125", "r127", "r130", "r133", "r135", "r337", "r342", "r345", "r355" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r71", "r84", "r85", "r124", "r271", "r274", "r275", "r356" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "us-gaap_IncomeTaxesPaidNet", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r59" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r59" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Other current and long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r59" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r89", "r90", "r91", "r100" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r94", "r95", "r100" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Convertible Preferred Stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r89", "r90", "r92", "r100", "r229" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Stock Options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r55", "r57", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r22", "r147" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished Goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r28", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "us-gaap_InventoryNet", "totalLabel": "Total Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r8", "r26", "r66", "r105", "r145", "r146", "r148", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r24", "r147" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r23", "r147" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-Progress" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r314" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r314" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r314" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r314" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Discount factor" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32", "r70", "r129", "r143", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r277", "r278", "r279", "r300", "r318", "r319" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r70", "r143", "r300", "r320", "r340", "r350" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r34", "r70", "r143", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r277", "r278", "r279", "r300", "r318", "r319", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "us-gaap_LiabilitiesFairValueDisclosure", "terseLabel": "Balance" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CURRENT LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r56" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r56", "r58", "r61" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r41", "r42", "r45", "r47", "r61", "r70", "r76", "r78", "r79", "r80", "r81", "r84", "r85", "r97", "r125", "r127", "r130", "r133", "r135", "r143", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r285", "r300", "r343", "r353" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "plxp_NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING TRANSACTIONS" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "TOTAL OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r125", "r127", "r130", "r133", "r135" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "OPERATING LOSS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "us-gaap_OperatingLeaseLiabilityCurrent", "negatedLabel": "Current lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Non-current lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r309" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r313", "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "us-gaap_OtherCommitment", "terseLabel": "Other Commitment, Total" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r33", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "plxp_NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "us-gaap_PreferredStockDividendsIncomeStatementImpact", "negatedLabel": "Preferred dividends" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15", "r185" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15", "r185" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; $0.001 par value; 930,000 shares authorized; none issued and outstanding at March 31, 2022 and December 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "us-gaap_ProceedsFromIssuanceOfCommonStock", "terseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r154", "r320", "r346", "r351" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r54" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r270", "r335", "r371" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r201", "r320", "r349", "r364", "r365" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r73", "r74", "r75", "r77", "r83", "r85", "r144", "r263", "r264", "r265", "r272", "r273", "r283", "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r121", "r122", "r126", "r131", "r132", "r136", "r137", "r138", "r212", "r213", "r336" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "TOTAL REVENUES", "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r67", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueProductLineMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service Benchmark [Member]" } } }, "localname": "SalesRevenueProductLineMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r25", "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r234", "r249", "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r202", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, marketing and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r14", "r15", "r199" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r14", "r15", "r199" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, number of units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "negatedLabel": "Exercised, cancelled, or forfeited, number of units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Exercised, cancelled, or forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, number of units (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, number of units, balance (in shares)", "periodStartLabel": "Outstanding, number of units, balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price, balance (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r253", "r254", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r65", "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r68", "r70", "r88", "r93", "r96", "r98", "r100", "r107", "r108", "r109", "r143", "r165", "r169", "r170", "r171", "r174", "r175", "r185", "r186", "r189", "r193", "r199", "r300", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r37", "r43", "r44", "r45", "r73", "r74", "r75", "r77", "r83", "r85", "r106", "r144", "r199", "r201", "r263", "r264", "r265", "r272", "r273", "r283", "r302", "r303", "r304", "r305", "r306", "r307", "r316", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization", "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables", "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events", "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r73", "r74", "r75", "r106", "r336" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-", "http://plxpharma.com/20220331/role/statement-note-1-background-and-organization", "http://plxpharma.com/20220331/role/statement-note-2-liquidity", "http://plxpharma.com/20220331/role/statement-note-2-liquidity-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-inventory-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details", "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-stock-option-activity-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-summary-of-warrant-activities-details", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-details-textual", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-maturity-of-operating-leases-details", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-carrying-amount-of-assets-and-liabilities-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-measured-at-fair-value-on-a-recurring-basis-details", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables", "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events", "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r19", "r20", "r70", "r142", "r143", "r300", "r320" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-changes-in-series-a-and-series-b-convertible-preferred-stock-and-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r69", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r201", "r203", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-7-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-2-liquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-cash-flow-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-tables", "http://plxpharma.com/20220331/role/statement-note-5-commitments-and-contingencies-tables", "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Convertible preferred stock, liquidation value" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r9", "r184" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Convertible preferred stock, par value (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Convertible preferred stock, shares authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Convertible preferred stock, shares issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Convertible preferred stock, shares outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": { "auth_ref": [ "r9", "r184" ], "calculation": { "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Preferred stock" } } }, "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r110", "r111", "r112", "r113", "r117", "r118", "r119" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "us-gaap_WarrantsAndRightsOutstandingMeasurementInput", "terseLabel": "Warrants and Rights Outstanding, Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-6-fair-value-measurements-details-textual" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-4-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r100" ], "calculation": { "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "totalLabel": "Total Potential Dilutive Shares (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-note-3-summary-of-significant-accounting-policies-potentially-dilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r87", "r100" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares of common shares, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://plxpharma.com/20220331/role/statement-consolidated-statements-of-operations-unaudited-" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r372": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r373": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r374": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r375": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r376": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r377": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r378": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" } }, "version": "2.1" } ZIP 49 0001437749-22-012225-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-012225-xbrl.zip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end